

CURRICULUM VITAE

I. PERSONAL INFORMATION

Name: **AGNIESZKA DOROTA CZECHOWICZ, M.D., PH.D.**
Title: Assistant Professor of Pediatrics
Stanford University School of Medicine
Address: Biomedical Innovations Bldg., Rm. 2351
240 Pasteur Dr., Palo Alto, CA. 94304
E-Mail: aneeshka@stanford.edu
Office Phone: 650-497-2218
ORCID iD: 0000-0003-2909-2669

II. EDUCATIONAL BACKGROUND

Education

- 9/2001 – 6/2005 **B.S.**, Biological Sciences with Honors, Chemistry minor.
Stanford University, Stanford, CA.
Student Representative to Stanford University Faculty Senate and Stanford University Board of Trustees. Due to family financial constraints compressed coursework and finished 3/2004 though degree conferred with intended cohort.
- 6/2006 – 6/2010 **Ph.D.**, Developmental Biology.
Stanford University, Stanford, CA.
Research Advisor: Prof. Irving L. Weissman, M.D.
Thesis Title: “*Gaining Access to the HSC Niche - Novel Non-Myeloablative Conditioning Approaches.*”
- 6/2006 – 1/2012 **M.D.**, Scholarly Concentration Molecular Basis of Medicine.
Stanford University School of Medicine, Stanford, CA.
Student-Body President.
- 7/2009 – 8/2009 Summer Institute of Entrepreneurship.
Stanford University, Graduate School of Business, Stanford, CA.
Mini-MBA program focused on new venture formation.

Postdoctoral Training

- 1/2012 – 12/2014 **Pediatric Internship & Residency**, Categorical and Integrated Research Tracks.
Boston Combined Residency Program, Boston Children’s Hospital/Boston Medical Center, Boston, MA.
Continuity Clinics in Pediatrics and Pediatric Genetics.
- 1/2012 – 1/2017 **Post-Doctoral Research Fellowship**, Stem Cell Biology.
Boston Children’s Hospital, Boston, MA.
Research Advisor: Prof. Derrick Rossi, Ph.D.
Advisor closed successful research laboratory at end of postdoctoral fellowship due to changing personal interests associated with successful company formation (Moderna Therapeutics, Intellia Therapeutics and Magenta Therapeutics).

- 1/2015 – 1/2017 **Pediatric Hematology/Oncology/Stem Cell Transplant Fellowship:** Year I-II.
Dana Farber Cancer Institute/Boston Children’s Hospital, Boston, MA.
Sub-Focus in Stem Cell Transplantation.
- 2/2017 – 12/2017 **Pediatric Hematology/Oncology/Stem Cell Transplant Fellowship:** Year III.
Stanford University/Stanford Children’s Health, Stanford, CA.
Sub-Focus in Bone Marrow Failure.

III. LICENSURES AND BOARD CERTIFICATIONS

Licensures

- 2014 Medical Licensure, Commonwealth of Massachusetts, expired 8/2017.
2016 Medical Licensure, Medical Board of California, expires 8/2028.
2016 DEA Licensure, expires 8/2026.

Board Certifications

- 2021 American Board of Pediatrics:
Board Certification in Pediatrics. Enrolled in MOC.
- 2023 American Board of Pediatrics:
Board Certification in Pediatric Hematology/Oncology. Enrolled in MOC.

IV. PROFESSIONAL APPOINTMENTS

Academic Appointments

- 1/2018 – present **Assistant Professor of Pediatrics – University Tenure Line (UTL)**
Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative
Medicine. Stanford University School of Medicine, Stanford, CA.

Direct a 12-person basic science and translational transplantation research laboratory currently composed of: 3 Postdoctoral fellows, 1 M.D./Ph.D. student, 2 Ph.D. students, 1 M.S. student, 2 Undergraduate students, 6 Research scientists and 1 Research technician.

Other Appointments

- 2018 – present **Member**, Stanford Institute for Stem Cell Biology and Regenerative Medicine.
2018 – present **Member**, Stanford Center for Definitive and Curative Medicine,
Co-Lead, Blood Stem Cell Engineering and Transplantation Platform.
2018 – present **Member**, Stanford Maternal and Child Health Research Institute.
2018 – present **Member**, Stanford Diabetes Research Center.
2018 – present **Member**, Stanford Immunology Program.
2018 – present **Member**, Stanford Bio-X.
2018 – present **Faculty Mentor**, NIH T32 Training Grant,
Medical Scientist Training Program.

- 2018 – 2022 **Faculty Mentor**, NIH T32 Training Grant,
Pediatric Nonmalignant Hematology and Stem Cell Biology.
- 2023 – present **Faculty Mentor**, NIH Multi-Institution U2C/TL1 Training Program,
LAUNCH: Learners to leAders in Urology, Nephrology, and non-Cancer
Hematology with Stanford, UCSF, UC Berkeley and UC Davis.

V. HONORS AND AWARDS

- 2001 Summer Student Award,
American Society of Hematology (ASH).
- 2005 Achaur Award for Outstanding Honors Presentation,
Stanford University.
- 2005 Firestone Medal for Excellence in Undergraduate Research,
Stanford University.
- 2005 Honors in Biological Sciences,
Stanford University.
- 2006 – 2009 Medical Scientist Fellowship,
Stanford University Medical Scholars Program.
- 2007 Young Scientist Travel Grant,
International Congress of Immunology (ICI).
- 2007 Trainee Research Award,
American Society of Hematology (ASH).
- 2007 Late-Breaking Abstract Recipient,
American Society of Hematology (ASH).
- 2007 Invitee Transplantation Press Conference,
American Society of Hematology (ASH).
- 2008 – 2009 Research Training Fellowship,
Howard Hughes Medical Institute (HHMI).
- 2008 – 2010 Soros Fellowship for New Americans,
Paul & Daisy Soros Foundation.
- 2010 Presenter Travel Award,
American Society of Hematology (ASH).
- 2011 California Institute of Regenerative Medicine (CIRM) Scholarship,
International Society of Stem Cell Research (ISSCR).
- 2014 Fred Lovejoy Award,
Boston Children's Hospital.
- 2014 Delegate to International Summit of Achievement,
Academy of Achievement.
- 2015 Potter Fellowship,
Boston Children's Hospital / Dana Farber Cancer Institute.
- 2016 Abstract Achievement Award,
American Society of Hematology (ASH).
- 2018 Lorry I. Lokey Faculty Scholar Award,
Stanford University School of Medicine.
- 2019 Harvey J. Cohen, M.D., Ph.D. Endowed Lectureship,
Lucile Packard Children's Hospital Stanford.

- 2019 Baxter Faculty Scholar Award,
Donald E. and Delia B. Baxter Foundation.
- 2020 New Investigator Award,
American Society of Transplantation and Cell Therapy (ASTCT).
- 2020 Young Investigator Award,
National Comprehensive Cancer Network (NCCN).
- 2020 Best Pre-clinical Publication Award,
World Antibody-Drug-Conjugate (ADC).
- 2021 Bronze Prize for Custom Animal Model Award (CAMA),
Taconic-Cyagen.
- 2021 Outstanding Poster Presentation Award,
American Society of Gene and Cell Therapy (ASGCT).
- 2022 David B. Frohnmayer Early Career Investigator Award,
Fanconi Anemia Research Foundation (FARF).
- 2022 Junior Faculty Scholar Award,
American Society of Hematology (ASH).
- 2022 Ernest McCulloch and James Till Award for the Best Basic Science Article,
Transplantation and Cell Therapy (TCT).
- 2023 Second Place Best PEDS Abstract Award,
Transplantation and Cell Therapy (TCT).
- 2024 Outstanding New Investigator Award,
American Society of Gene and Cell Therapy (ASGCT).
- 2025 Nominee for Board of Directors,
American Society of Gene and Cell Therapy (ASGCT).
- 2025 Nominee for Inspiring Early Academic Career Award,
Stanford Faculty Women's Forum.
- 2025 Presenter Travel Award,
International Fetal Medicine and Surgery Society (IFMSS).
- 2026 Nominee for Board of Directors,
American Society of Gene and Cell Therapy (ASGCT).

VI. SCHOLARLY PUBLICATIONS

Peer-Reviewed Journal Articles: 31 Published Original Research Articles

22 Since Faculty Appointment in 2018, with 16 as Senior/Corresponding Author †

1. **Czechowicz A**, Kraft D, Weissman IL, Bhattacharya D. "Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell Niches." Science. 2007 Nov 23; 318(5854):1296-9.
2. Rossi DJ, Seita J, **Czechowicz A**, Bhattacharya D, Bryder D, Weissman IL. "Hematopoietic Stem Cell Quiescence Attenuates DNA Damage Response and Permits DNA Damage Accumulation During Aging." Cell Cycle. 2007 Oct 1; 6(19):2371-6.

3. Bhattacharya D*, **Czechowicz A***, Ooi L, Rossi D, Bryder D, Weissman IL. “Niche Recycling Through Division-Independent Egress of Hematopoietic Stem Cells.” J Exp Med. 2009 Nov 23; 206(12):2837-50. *[Co-first author. *]*
4. Ahn GO, Tseng D, Liao CH, Dorie MJ, **Czechowicz A**, Brown JM. “Inhibition of Mac-1 (CD11b/CD18) Enhances Tumor Response to Radiation by Reducing Myeloid Cell Recruitment.” Proc Natl Acad Sci. 2010 May 4; 107(18):8363-8.
5. Edris B, Willingham S, Weiskopf K, Volkmer A, Volkmer J, Muhlenberg T, Montgomery K, Contreras-Trujillo H, **Czechowicz A**, Fletcher J, West R, Weissman I, Van de Rijn M. “Anti-KIT Monoclonal Antibody Inhibits Imatinib-Resistant Gastrointestinal Stromal Tumor Growth.” Proc Natl Acad Sci. 2013 Feb 26; 110(9):3501-6.
6. Derderian C, Togarrati P, King C, Moradi P, Reynaud D, **Czechowicz A**, Weissman I, MacKenzie T. “In Utero Depletion of Fetal Host Hematopoietic Stem Cells Improves Engraftment Following Neonatal Transplantation in Mice.” Blood. 2014 Aug 7; 124(6):973-80.
7. Dvorak CC, Horn BN, Puck JM, **Czechowicz A**, Shizuru JA, Ko RM, Cowan MJ. “A Trial of Plerixafor Adjunctive Therapy in Allogeneic Hematopoietic Cell Transplantation with Minimal Conditioning for Severe Combined Immunodeficiency.” Pediatr Transplant. 2014 Sep; 18(6):602-8.
8. Dvorak CC, Horn BN, Puck JM, Adams S, Veys P, **Czechowicz A**, Cowan MJ. “A Trial of Alemtuzumab Adjunctive Therapy in Allogeneic Hematopoietic Cell Transplantation with Minimal Conditioning for Severe Combined Immunodeficiency.” Pediatr Transplant. 2014 Sep; 18(6):609-16.
9. Palchadhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes DB, Tate TA, **Czechowicz A**, Kfoury Y, Ruchika F, Rossi DJ, Verdine GL, Mansour MK, Scadden DT. “Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplantation Using a Hematopoietic-Cell-Specific Internalizing Immunotoxin.” Nat Biotechnol. 2016 Jul; 34(7):738-45. *[Designed and conducted several critical experiments, as well as contributed to data analysis and interpretation. Contributed to the critical revision of the manuscript for important intellectual content.]*
10. Lu R, **Czechowicz A**, Seita J, Juang D, Weissman IL. “Clonal-Level Lineage Commitment Pathways of Hematopoietic Stem Cells In Vivo.” Proc Natl Acad Sci. 2019 Jan 22; 116(4):1447-1456. *[Guided scientific direction of significant portion of the project. Assisted with a majority of the experiments. Contributed to data interpretation and manuscript revision for important intellectual content.]*
11. **Czechowicz A*‡**, Palchadhuri R*, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT‡, Rossi DJ‡. “Selective Hematopoietic Stem Cell Ablation using CD117 Antibody-Drug-Conjugates Enables Safe and Effective HSC Transplantation with Immunity Preservation.” Nat Commun. 2019 Feb 6; 10(1):617. *[Co-first author and co-corresponding author. Spear-headed initial conception of the project. Conducted all experiments, with many experiments being performed in independent*

research laboratory after start of faculty position. Contributed to all aspects of manuscript preparation and was corresponding author through the publication process.]

12. Li Z*, **Czechowicz A**[‡], Scheck A, Rossi DJ[‡], Murphy PM[‡]. “Hematopoietic Chimerism and Donor-Specific Skin Allograft Tolerance after Non-Genotoxic CD117 Antibody-Drug-Conjugate Conditioning in MHC-Mismatched Allotransplantation.” Nat Commun. 2019 Feb 6; 10(1):616. *[Co-first author and co-corresponding author. Spear-headed initial conception of the project. Provided intellectual and technical assistance with design of all experiments and interpretation of data. Contributed to all aspects of manuscript preparation and was corresponding author through the publication process.]*
13. Pang WW*, **Czechowicz A***, Logan AC, Bhardwaj R, Poyser J, Park CY, Weissman IL, Shizuru JA. “Anti-CD117 Antibody Depletes Normal and Myelodysplastic Syndrome Hematopoietic Stem Cells in Xenografted Mice.” Blood. 2019 May 9; 133(19):2069-2078. *[Co-first author. Spear-headed initial conception of the first half of the project. Conducted experiments, generated data, analyzed results, and determined interpretation of data. Contributed to the critical revision of the manuscript for important intellectual content.]*
14. Kwon H, Logan AC, Chhabra A, Pang WW, **Czechowicz A**, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Thway TM, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA. “Anti-Human CD117 Antibody-Mediated Bone Marrow Niche Clearance in Non-Human Primates and Humanized NSG Mice.” Blood. 2019 May 9; 133(19):2104-2108. *[Spear-headed initial conception of critical section of the project. Provided technical assistance with major portion of experiments and interpretation of data. Contributed to the critical revision of the manuscript for important intellectual content.]*
15. Gao C, Schroeder JA, Xue F, Jing W, Cai Y, Scheck A, Subramaniam S, Rao S, Weiler H, **Czechowicz A**[‡], Shi Q[‡]. “Non-Genotoxic Antibody-Drug-Conjugate Conditioning Enables Safe and Effective Platelet Gene Therapy of Hemophilia A Mice.” Blood Adv. 2019 Sep 24; 3(18):2700-2711. *[Co-corresponding author. Spear-headed initial conception of the project. Provided continued intellectual and technical assistance with design of all experiments and interpretation of data. Contributed to the critical revision of the manuscript for important intellectual content.]*
16. Kraft DL, Walck ER, Carrasco A, Crocker MD, Song L, Long MG, Mosse MA, Nadeem B, Imanbyev GT, **Czechowicz A**, McCullough MJ. “The MarrowMiner: A Novel Minimally Invasive and Effective Device for the Harvest of Bone Marrow.” Biol Blood Marrow Transplant. 2020 Feb; 26(2):219-229. *[Spear-headed compilation of data and generation of the manuscript. Mentored research team and provided intellectual and technical assistance with interpretation of data. Contributed to writing the manuscript and played an active role throughout the publication process guiding ultimate publication with offer to be senior and corresponding author, though elected to not do this as outside of core interest area.]*

17. Ho PY, Zhang Z, Hayes ME, Curd A, Dib C, Rayburn M, Tam SZ, Srivastava T, Hriniaik B, Li X, Leonard S, Wang L, Tarighat S, Sim DS, Fiandaca M, Coull JM, Ebens A[‡], Fordyce M, **Czechowicz A[‡]**. “Peptide Nucleic Acid-Dependent Artifact Can Lead to False-Positive Triplex Gene Editing Signals.” Proc Natl Acad Sci. 2021 Nov 9; 118(45). [*Senior and co-corresponding author.*]
18. Chan YY, Ho PY, Swartzrock L, Rayburn M, Nofal R, Thongthip S, Weinberg KI, **Czechowicz A[‡]**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Transplant Cell Ther. 2023 Mar; 29(3):164. e1-164.e9. [*Senior and corresponding author. Awarded 2022 Ernest McCulloch & James Till Award for the Best Basic Science article. Award presented at the 2023 Transplantation and Cell Therapy Meeting, Orlando, FL (2/18/2023).*]
19. Igarashi KJ, Kucinski I, Chan YY, Tan TK, Khoo HM, Kealy D, Bhadury J, Hsu I, Ho PY, Niizuma K, Hickey JW, Nolan GP, Bridge KS, **Czechowicz A**, Gottgens B, Nakauchi H, Wilkinson AC. “Physioxia Improves the Selectivity of Hematopoietic Stem Cell Expansion Cultures.” Blood Adv. 2023 Jul 25; 7(14):3366-3377. [*Spear-headed important component of the project showcasing disease-related application of HSC expansion approach. Provided intellectual and technical assistance with planning experiments and interpretation of data. Contributed to the critical revision of the manuscript for important intellectual content.*]
20. Sharma A, **Czechowicz A**, Mavers M, Chao N, DiPersio J, Reddy P, Perales MA, Smith M. “Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force.” Transplant Cell Ther. 2024 Jun; 30(6):559-564. [*Contributed to the design of study, interpretation of data, and writing and revision of the manuscript.*]
21. Denis M, Swartzrock L, Willner H, Bubb QR, Haslett E, Chan YY, Chen A, Krampf MR, **Czechowicz A[‡]**. “Hematopoiesis After Anti-CD117 Monoclonal Antibody Treatment in the Settings of Wild-type and Fanconi Anemia Mice.” Haematologica. 2024 Sep 1; 109(9):2920-2929. [*Senior and corresponding author.*]
22. Swartzrock L, Dib C, Denis M, Willner H, Ho K, Haslett E, Han J, Pan W, Byrne-Steele M, Brown B, Krampf MR, Girsen A, Blumenfeld YJ, El-Sayed YY, Roncarolo MG, MacKenzie TC, **Czechowicz A[‡]**. “In Utero Hematopoietic Stem Cell Transplantation for Fanconi Anemia.” Blood Adv. 2024 Sep 10;8(17):4554-4558. [*Senior and corresponding author.*]
23. Chan YY, Ho PY, Dib C, Swartzrock L, Rayburn M, Willner H, Ethan K, Denis M, Cool T, **Czechowicz A[‡]**. “Targeted Hematopoietic Stem Cell Depletion Through SCF-Blockade.” Stem Cell Res Ther. 2024 Oct 29;15(1):387. [*Senior and corresponding author.*]
24. Bubb QR, Balood M, Seir GE, Swartzrock L, Haslett E, Ho K, Xu P, Wiltz SG, Sotillo E, Gruber TA, Richards RM, Mackall CL, **Czechowicz A[‡]**. “Development of Multivalent CAR T Cells as Dual Immunotherapy and Conditioning Agents.” Mol Ther Oncol. 2025 Jan 30;33(1):200944. [*Senior and corresponding author. Selected as cover article. Awarded 2026 Best of Molecular Therapy Oncology Award. Award to be presented at the 2026 American Society of Gene and Cell Therapy (ASGCT) Meeting, Boston, MA (5/14/2026).*]

25. Charlesworth CT, Homma S, Amaya AK, Dib C, Vaidyanathan S, Tan T, Miyauchi M, Nakauchi Y, Suchy FP, Wang S, Igarashi KJ, Cromer MK, Dudek AM, Amorin A, **Czechowicz A[‡]**, Wilkinson AC[‡], Nakauchi H[‡]. “Highly Efficient In Vivo Hematopoietic Stem Cell Transduction Using an Optimized Self-Complementary Adeno-Associated Virus.” Mol Ther Methods Clin Dev. 2025 Feb 21;33(1):101438. [Co-corresponding author. Spear-headed parallel project, provided intellectual and technical assistance with experiments and interpretation of data. Contributed to the critical revision of the manuscript for important intellectual content.]
26. Dib C, Queenan JA, Swartzrock L, Willner H, Denis M, Ahmed N, Moulana Zada F, Borges B, Charlesworth CT, Lum T, Yates BP, Kwon C, Scorzo AV, Davis S, Davies JR, He R, Xie J, Gao G, MacKenzie T, Liu DR[‡], Newby GA[‡], **Czechowicz A[‡]**. “GFP-on Mouse Model for Interrogation of *In Vivo* Gene Editing.” Nat Commun. 2025 Jul 31;16(1):7017. [Senior and co-corresponding author.]
27. Agarwal R, Bertaina A, Soco C, Long-Boyle JR, Saini G, Kunte N, Hiroshima L, Chan YY, Willner H, Krampf MR, Nofal R, Barbarito G, Sen S, Van Hentenryck M, Walck E, Scheck A, Perriman RJ, Bouge A, Istomina E, Naz Din H, Klinger EF, Cheng JC, Wlodarski MW, Boelens JJ, Shizuru JA, Pang WW, Weinberg K, Parkman R, Roncarolo MG, Porteus M^{*}, **Czechowicz A[‡]**. “Irradiation- and Busulfan-Free Stem Cell Transplantation in Fanconi Anemia Using an Anti-CD117 Antibody: A Phase 1b Trial.” Nat Med. 2025 Sep; 31(9):3183-3190. [Co-senior and corresponding author.]
28. Bubb QR, Sotillo E, Richards RM, Mackall CL, Gruber TA, **Czechowicz A[‡]**. “Transcriptomic Diversity of Pediatric Acute Leukemia Genetic Drivers Correlates with Clinical Outcome and Expression of Stemness-Related Genes.” Cancer Med. 2025 Nov; 14(21):e71325. [Senior and corresponding author. Selected as cover article.]
29. Lum T[‡], Lee C, MacKenzie T, Lianoglou B^{*}, **Czechowicz A[‡]**. “Attitudes Toward Prenatal Interventions in the Fanconi Anemia Community.” Prenat Diagn. 2026 Feb 19. Epub ahead of print. [Co-senior and co-corresponding author.]
30. Seir G, Bubb QR, Sotillo E, Gruber T, Richards RM, **Czechowicz A[‡]**. “Development and Characterization of Anti-CXCR4 Chimeric Antigen Receptor T Cells.” Transl Oncol. 2026 Apr; 66:102711. Epub 2026 Mar 3. [Senior and corresponding author.]
31. Dib C, Queenan JA, Willner H, Swartzrock L, Charlesworth CT, Denis M, Davis JR, Mepani R, Castro M, Wilson RC, Naukauchi H, Liu DR, **Czechowicz A[‡]**. “Correction of Severe Combined Immunodeficiency Disorder in a Novel Mouse Model Using Non-Genotoxic Conditioning and Base-Editors.” Mol Therapy. Accepted 3/21/26. Initial Submission 2/26/2025. [Senior and corresponding author.]

Submitted Original Research Articles: 1 in Revision and 3 in Review

32. Wang W, Mohammed A, Arreola M, Zheng Z, Moon Y, Khan H, Wang J, Krampf M, Cipriano A, Li L, Willner L, Ramachandran A, **Czechowicz A**, Pasca A, Winn V, Bendall S, Bacchetta R, Sebastiano V, Weinacht K. “Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells.” *Nature*. *In Revision*. *Initial Submission 12/10/2025*.
33. Charlesworth CT[‡], Homma S, Suchy F, Chang A, Aviles V, Wang S, Bhadury J, Amaya AK, Gulati Y, Kuga Y, Camarena J, Niizuma K, Zhang J, Tan TK, Mepani RJ, Igarashi K, **Czechowicz A**[‡], Nakauchi H[‡]. “Secreted Particle Information Transfer (SPIT) – Design Principles for Human Cell-based Vectors for in vivo Genome Engineering.” *Cell Reports Medicine*. *In Review*. *Submitted 2/19/26*. [*Co-corresponding author*.]
34. Soco C, Chan YY, Sen S, Willner H, Klinger E, Nofal R, Singh M, Parkman R, MG Roncarolo, Weinberg K, Porteus M, Bertaina A, Agarwal R, **Czechowicz A**[‡]. “Progressive Signaling Dysfunction in Fanconi Anemia Bone Marrow Failure by Proteomics and Single-Cell Transcriptomics.” *Communications Medicine*. *In Review*. *Initial Submission 2/25/2026*. [*Senior and corresponding author*.]
35. Ali M, Joseph C, Xu X, Gaskin D, Kabore D, Mukendi J, Idowu A, Hegazy AM, Scheck A, **Czechowicz A**, Fitzhugh CD. “Non-Genotoxic Conditioning Increases Donor Chimerism in a Mismatched Murine Transplant Model for Sickle Cell Disease.” *Cell Reports Medicine*. *In Review*. *Initial Submission 3/5/2026*.

Other Articles, Reviews, & Editorials: 9 Total

1. **Czechowicz A**, Kraft D, Weissman IL. “Development of a Robust Human Adaptive Immune System in CD34+ Enriched Peripheral Blood Transplanted Mice Through Use of Anti-Murine-C-Kit Monoclonal Antibody, ACK2.” *The Stanford Biologist*. 2005 May; 5: 79-86.
2. Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants (incl. **Czechowicz A**). "Improving Cellular Therapy for Primary Immune Deficiency Diseases: Recognition, Diagnosis, and Management." *J Allergy Clin Immunol*. 2009 Dec; 124(6):1152-60.
3. **Czechowicz A**, Weissman IL. “Purified Hematopoietic Stem Cell Transplantation: The Next Generation of Blood and Immune Replacement.” *Immunol Allergy Clin North Am*. Review. 2010 May; 30(2):159-71. [*First and corresponding author*.]
4. **Czechowicz A**, Weissman IL. “Purified Hematopoietic Stem Cell Transplantation: The Next Generation of Blood and Immune Replacement.” *Hematol Oncol Clin North Am*. Review. 2011 Feb; 25(1):75-87. [*First and corresponding author*.]
5. Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinuer MC, Dvorak CC, Filipovich AH, Fleisher

TA, Gaspar HB, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; Workshop Participants (incl. **Czechowicz A**). "Primary Immune Deficiency Treatment Consortium (PIDTC) report." *J Allergy Clin Immunol*. 2014 Feb; 133(2):335-47.

6. Cannon P, Asokan A, **Czechowicz A**, Hammond P, Kohn DB, Lieber A, Malik P, Marks P, Porteus M, Verhoeven E, Weissman D, Weissman I, Kiem HP. "Safe and Effective *In Vivo* Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development." *Hum Gene Ther*. 2021 Jan; 32(1-2):31-42. [*Contributed important intellectual content and contributed to editing of the manuscript.*]
7. Van Hentenryck M, Li Z, Murphy P, **Czechowicz A**[‡]. "Antibody-Based Preparative Regimens for Cell, Tissue and Organ Transplantation." *OBM Transplantation*. Invited Review. 2022; 6(3): 162. [*Senior and corresponding author.*]
8. Szade A, Gulati G, **Czechowicz A**. "Mobilization of Hematopoietic Cells from the Bone Marrow to the Peripheral Blood: Challenges and New Therapeutic targets." Invited Editorial. *Front Pharmacol*. 2025; (16):1592559. [*Senior author.*]
9. John T, **Czechowicz A**[‡]. "Clinical Hematopoietic Stem Cell-Based Gene Therapy." Invited Review. *Mol Ther*. 2025 Apr 24; S1525-0016(25):00308-9. [*Senior and corresponding author.*]

Book Chapters: 2 Total

1. Bonfim C, Cancio M, **Czechowicz A**, Davies S, Dufour C, MacMillan M, R Latour, Srikanthan M, Wagner J (alphabetical order). "Chapter 3 Hematologic Issues" in the 6th Edition Fanconi Anemia Clinical Care Guidelines. Fanconi Cancer Foundation. Book Chapter. 2023. [*Provided intellectual content as an author. Additionally, contributed as an editor and co-chair.*]
2. **Czechowicz A**, Fiesco-Roa M, Kennedy J, Lianoglou B, Lipton J, Matalon D, McGuinness M, Moreau L, Olson S, Shimamura A, Tryon J (alphabetical order). "Chapter 2 Diagnosis of Fanconi Anemia: Testing and Genetic Counseling" in the 6th Edition Fanconi Anemia Clinical Care Guidelines. Fanconi Cancer Foundation. Book Chapter. *In Review. Initial Submission 10/26/2024.* [*Provided intellectual content as an author.*]

Abstracts: Oral Presentations (Since Faculty Appointment Only): 50 Total

Note: Given the extended timelines of animal and clinical transplantation research which result in publication lags, peer-reviewed presentations are alternative avenue to share interim results.

1. **Czechowicz A**, Palchadhuri R, Scheck A, Hu Y, Winau F, Hoggatt J, Saez B, Mansour MK, Sykes DB, Scadden D, Rossi D. "Immune Sparing Conditioning for BMT/HSCT Using Anti-Ckit Immunotoxins." Abstract. A Czechowicz presented at the 2018 American Society for Bone and Marrow Transplantation, Salt Lake City, UT (2/23/2018).

2. Gao C, Schroeder A, **Czechowicz A**, Shi Q. " Safe and Effective Platelet-Targeted Gene Therapy of Hemophilia A Enabled Using Non-Genotoxic, Immunotoxin-Based Conditioning." Abstract. Q Shi presented at the 2018 Thrombosis & Hemostasis Societies of North America, San Diego, CA (3/10/2018).
3. **Czechowicz A**, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Mansour MK, Sykes DB, Winau F, Scadden D, Rossi D. "Selective HSC Ablation Using Anti-CD117 Antibody-Drug-Conjugate Enables Safe and Effective Murine and Human Hematopoietic Stem Cell Transplantation." Abstract. A Czechowicz presented at the 2018 European Society for Blood and Marrow Transplantation, Lisbon, Portugal (3/19/2018).
4. **Czechowicz A**, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang W, Mansour MK, Tate T, Walck W, Shizuru J, Winau F, Scadden DT, Rossi DJ. " Selective HSC Ablation Using Anti-CD117 Antibody-Drug-Conjugate Enables Safe and Effective Murine and Human Hematopoietic Stem Cell Transplantation." Abstract. A Czechowicz presented at the 2018 American Society of Gene & Cell Therapy, Chicago, IL (5/16/2018).
5. Gao C, Schroeder A, **Czechowicz A**, Shi Q. " Safe and Effective Platelet-Targeted Gene Therapy of Hemophilia A Enabled Using Non-Genotoxic, Antibody-Drug-Conjugate Conditioning." Abstract. Q Shi presented at the 2018 American Society of Gene & Cell Therapy, Chicago, IL (5/16/2018).
6. Li Z, **Czechowicz A**, Scheck A, Rossi D, and Murphy P. "Robust Hematopoietic Mixed Chimerism and Donor-specific Skin Allograft Tolerance after Non-genotoxic anti-CD117 Immunotoxin Conditioning and Donor Bone Marrow Allotransplantation." Abstract. Z Li presented at the 2018 American Transplant Congress, Seattle, WA (6/4/2018).
7. **Czechowicz A**, Palchaudhuri R, Scheck A, Hoggatt J, Saez B, Tate T, Scadden DT, Rossi DJ. "Selective HSC-Ablation Using Anti-CD117 Antibody Drug Conjugate Enables Safe and Effective Hematopoietic Stem Cell Transplantation." Abstract. A Czechowicz presented at the 2018 International Fetal Immunology and Transplantation Society, Stockholm, Sweden (6/12/2018).
8. Chan S, Ko E, Favaro P, Scheck A, **Czechowicz A**. "Development of Safe and Non-Genotoxic anti-c-Kit (CD117) Antibody-based Conditioning Regimens for Hematopoietic Stem Cell Transplantation in Fanconi Anemia." Abstract. A Czechowicz presented at the 2018 Fanconi Anemia Research Foundation Scientific Symposium, Newport Beach, CA (9/29/2018).
9. Gao C, Schroeder JA, Xue F, Jing W, Subramaniam S, Weiler H, **Czechowicz A**, Shi Q. "Using non-genotoxic, antibody-drug-conjugate conditioning enables safe and effective platelet-specific FVIII gene therapy of hemophilia A." Q Shi presented at the 2019 American Society of Gene and Cell Therapy, Boston, MA (4/29/2019).
10. **Czechowicz A**, Cory J, Shah D, Roncarolo M. "Non-genotoxic conditioning for hematopoietic cell transplantation in Fanconi Anemia." Abstract. A Czechowicz presented at the 2019 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Chicago, IL (9/19/2019).

11. **Czechowicz A**, Roncarolo MG, Beard B, Choi G, Law K, Nicoletti E, Schwartz JD, Soni S. “A Phase I Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Fanconi Anemia, Complementation Group-A: Initial Patient Experience.” Abstract. A Czechowicz presented at the 2019 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Chicago, IL (9/21/2019).
12. **Czechowicz A**, Rio P, Bueren J, Beard B, Nicoletti E, Schwartz JD, and Soni S. “Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor Cells.” Abstract. S Soni presented at the 2019 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Annual Meeting, Orlando, FL (2/20/2020).
13. **Czechowicz A**, Agarwal R, Soni S, Beard B, Law K, Nicoletti E, Rio P, Bueren J, Schwartz J, Roncarolo M. “Preliminary Results from a U.S. Phase 1 Study of Lentiviral Ex-vivo Gene Therapy for Patients with Fanconi Anemia Type A.” Abstract. A Czechowicz presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/16/2020).
14. **Czechowicz A**, Pang W, Van Hentenryck M, Thongthip S, Chan S, Walck E, Scheck A, Dejene B, Kwon H, Le A, Dvorak C, Long-Boyle J, Brown J, Logan A, Parkman R, Weissman I, Bertaina A, Weinberg K, Roncarolo M, Shizuru J, Agarwal R. “JSP191 Antibody Conditioning for Hematopoietic Cell Transplantation: Anticipating a New Therapy for Fanconi Anemia” Abstract. A Czechowicz presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/16/2020).
15. MacKenzie T, Frascoi M, Sper R, Lianoglou B, Gonzalez-Velez J, Dvorak C, Kharbanda S, **Czechowicz A**, Vichinsky E. “In utero stem cell transplantation in patients with hemoglobin disorders: anticipating a new therapy for Fanconi Anemia.” Abstract. T MacKenzie presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/16/2020).
16. **Czechowicz A**, Agarwal R, Sevilla J, Rio P, Navarro S, Beard B, Law K, Choi G, Zeini M, Nicoletti E, Wagner J, Booth C, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia, Complementation Group A: Updated Results from Ongoing Global Clinical Studies of RP-L102.” Abstract. A Czechowicz presented virtually at the 2020 American Society of Hematology (ASH) Annual Meeting, Held online (12/7/2020).
17. **Czechowicz, A**. “Gene Therapy for Fanconi Anemia [Group A]: Interim Results from RP-L102 Global Clinical Trials.” Abstract. A Czechowicz presented virtually at the 2021 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (7/8/2021).

18. **Czechowicz A**, Booth C, Agarwal R, , Zubicaray J, Río P, Navarro S, Ancliff P, Sebastian E, Law K, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Wagner J, Rao G, Thrasher A, Schwartz J, Bueren J, Roncarolo M, Sevilla J. “Ex vivo Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2022 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Washington, DC (5/16/2022).
19. Nofal R, Chan YY, Sen S, Figueroa UJ, Hoang H, Thongthip S, Choi G, Nicoletti E, Schwartz J, Weinberg K, Rodriguez A, Agarwal R, Roncarolo MG, **Czechowicz A**. “Assessment of hematopoietic stem, progenitor and immune cells in Fanconi Anemia-Type A patients after ex vivo lentiviral FANCA gene therapy with RP-L102.” Abstract. R Nofal presented at the 2022 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Austin, TX (9/10/2022).
20. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O’Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. “Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the Best Abstracts at the Tandem meeting session, 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Annual Meeting, Orlando, FL (2/20/2023). **Second Place Award for Best Abstract.*
21. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, S Navarro, Chetty K, O’Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. “Lentiviral-mediated Gene Therapy for Fanconi Anemia [Group A]: Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Los Angeles, CA (5/18/2023).
22. Swartzrock L, Dib C, Willner H, Haslett E, Krampf M, Girsen A, Blumenfeld Y, El-Sayed Y, Roncarolo MG, MacKenzie TC, **Czechowicz A**. “In Utero Hemopoietic Stem Cell Transplantation for Fanconi Anemia.” Abstract. A Czechowicz presented at the 2023 7th International Fetal Immunology and Transplantation Society IFeTIS Conference, Edinburgh, Scotland (6/16/2023).
23. Swartzrock L, Dib C, Willner H, Haslett E, Krampf M, Girsen A, Blumenfeld Y, El-Sayed Y, Roncarolo MG, MacKenzie TC, **Czechowicz A**. “In Utero Hemopoietic Stem Cell Transplantation for Fanconi Anemia.” Abstract. L Swartzrock presented at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (9/30/2023).
24. Agarwal R, Bertaina A, Soco C, Saini G, Kunte N, Chan YY, Willner H, Krampf M, Nofal R, Barbarito G, Sen S, Felber M, Van Hentenryck M, Walck E, Scheck A, Thongthip S, Logan A, Dougall K, Bouge A, Boelens JJ, Long-Boyle J, Weissman I, Shizuru J, Pang W, Weinberg K, Parkman R, Roncarolo M, Porteus M, **Czechowicz A**. “Radiation and Busulfan-free Transplant Using JSP191 Antibody Conditioning and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Grafts.” Abstract. R Agarwal presented at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (9/30/2023).

25. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, S Navarro, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. “Lentiviral-mediated Gene Therapy for Fanconi Anemia [Group A]: Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2023 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (10/1/2023).
26. Swartzrock L, Dib C, Willner H, Haslett E, Ho K, Krampf M, Girsen A, Blumenfeld Y, El-Sayed Y, Roncarolo MG, MacKenzie TC, **Czechowicz A**. “In Utero Hemopoietic Stem Cell Transplantation for Fanconi Anemia.” Abstract. L Swartzrock presented at the 6th Annual Stanford Maternal and Child Health Research Institute (MCHRI) Symposium, Stanford, CA (10/19/2023).
27. Agarwal R, Bertaina A, Soco C, Saini G, Kunte N, Hiroshima L, Chan YY, Willner H, Krampf M, Nofal R, Barbarito G, Sen S, Felber M, Van Hentenryck M, Walck E, Scheck A, Thongthip S, Logan A, Dougall K, Bouge A, Boelens JJ, Long-Boyle J, Weissman I, Shizuru J, Pang W, Weinberg K, Parkman R, Roncarolo M, Porteus M, **Czechowicz A**. “Radiation and Busulfan-free Hematopoietic Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia.” Abstract. R Agarwal presented at the 2023 American Society of Hematology (ASH) Annual Meeting, San Diego, CA (12/9/2023).
28. Bubb QR, Balood M, Seir G, Swartzrock L, Haslett E, Ho K, Wiltz S, Sotillo E, Richards RM, Gruber TA, Mackall CL, **Czechowicz A**. “Development of Extracellularly Linked Concatemeric Trivalent Cytokine (ELeCTriC) Chimeric Antigen Receptor (CAR) T-Cells as Dual Conditioning and Immunotherapeutic Agents.” Abstract. QR Bubb presented at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore, MD (5/8/2024).
29. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, S Navarro, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Rothe M, Bastone A, John-Neek P, Schambach A, Wang W, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. “Lentiviral-Mediated Gene Therapy (RP-L102) for Fanconi Anemia [Group A] is Associated with Polyclonal Integration Patterns in the Absence of Conditioning.” Abstract. A Czechowicz presented at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore, MD (5/10/2024).
30. Agarwal R, Bertaina A, Porteus M, **Czechowicz A**. “Haploidentical Transplant Experience for Patients with Fanconi Anemia – Can We Eliminate TBI and Busulfan from Conditioning Regimens?” Abstract. A Czechowicz presented at the 2024 Fanconi Cancer Foundation (FCF) Scientific Symposium, Charlotte, NC (9/21/2024).

31. Sevilla J, Booth C, **Czechowicz A**, Zubicaray J, Río P, S Navarro, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Rothe M, Bastone A, John-Neek P, Schambach A, Wang W, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA, Agarwal R. “Lentiviral-Mediated Gene Therapy (RP-L102) for Fanconi Anemia [Group A] is Associated with Polyclonal Integration Patterns in the Absence of Conditioning.” Abstract. J Seville presented at the 2024 ESH-EBMT-EHA-IPIG 3rd Translational Research Conference, Paris, France (11/15/2024).
32. Swartzrock L, Liu L, Hoang H, Ho K, Neoman N, Krampf M, Sakamoto KM, **Czechowicz A**. “Disease Correction of a Diamond-Blackfan Anemia Mouse Model Using Non-Genotoxic Conditioning and Hematopoietic Stem Cell Transplantation.” Abstract. L Swartzrock presented at the 2024 American Society of Hematology (ASH) Annual Meeting, San Diego, CA (12/7/2024).
33. Soco C, Krampf M, Chan YY, Willner H, Kunte N, Saini G, Weinberg K, Parkman R, Agarwal R, Bertaina A, Porteus M, **Czechowicz A**. “Hematopoietic Recovery in Fanconi Anemia Patients Utilizing a Novel Anti-CD117 Antibody-Containing, Irradiation/Busulfan-Free Haploidentical Hematopoietic Stem Cell Transplant Regimen.” A Czechowicz presented at the 2025 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Honolulu, HI (2/13/2025).
34. Swartzrock L, Liu L, Willner H, Ho K, Neoman N, Krampf M, Sakamoto KM, **Czechowicz A**. “Disease Correction of a Diamond-Blackfan Anemia Mouse Model Using Non-Genotoxic Conditioning and Hematopoietic Stem Cell Transplantation.” Abstract. A Czechowicz presented at the 2025 Diamond Blackfan Anemia (DBA) International Collaboration Conference, Atlanta, GA (3/30/2025).
35. Soco C, Chan YY, Sen S, Acharya S, Willner H, Krampf MR, Klinger E, Roncarolo MF, Bertaina MG, Bertaina A, Porteus M, Weinberg K, Agarwal A, **Czechowicz A**. “Insights into Progressive Bone Marrow Dysfunction in Fanconi Anemia Through Proteomic and Transcriptomic Investigation.” Abstract. C Soco presented at the 2025 Fanconi Cancer Foundation (FCF) Scientific Symposium, Minneapolis, MN (9/27/2025).
36. Swartzrock L, Lum T, Dib C, Willner H, Denis M, Ho K, Lee C, Roncarolo MG, Girsen A, Blumenfeld Y, El-Sayed Y, Lianglou B, MacKenzie TC, **Czechowicz A**. “Development of Prenatal Treatments for Fanconi Anemia.” Abstract. A Czechowicz presented at the 42nd Annual Meeting of the International Fetal Medicine and Surgery Society (IFMSS), Napa, CA (10/15/2025). **Travel Award Recipient.*
37. Bertaina A, **Czechowicz A**, Hiroshima L, Kunte N, Klinger E, Saini G, John T, Alexander J, Shyr D, Shah A, Klein O, Long Boyel J, Boelens J, Wlodarsky M, Shizuru J, Arreola V, Parkman R, Weinber K, Porteus M, Agarwal A. “Can We Eliminate TBI/Busulfan and GvHD in Fanconi Anemia Transplantation? Results from a Prospective Haploidentical Transplant Approach.” Abstract. A Bertaina presented at the 2026 European Society for Blood and Marrow Transplant (EBMT) Annual Meeting, Madrid, Spain (3/23/2026).

A. Abstracts: Posters Presentations (Since Faculty Appointment Only): 44 Total

1. Pang WW, **Czechowicz A**, Poyser J, Park CY, Weissman IL, Shizuru JA. "Anti-Human CD117 Antibodies Mediate Clearance of Myelodysplastic Syndrome Hematopoietic Stem Cells and Facilitate Establishment of Normal Hematopoiesis in Transplantation." Abstract. Poster. W Pang presented at the 2018 American Society for Bone and Marrow Transplantation (ASBMT), Salt Lake City, UT (2/23/2018).
2. **Czechowicz A**, Palchaudhuri R, Li Z, Scheck A, Hu Y, Hoggatt J, Saez B, Pang W, Mansour MK, Tate T, Chan Y, Walck W, Wernig G, Shizuru J, Murphy PM, Winau F, Scadden DT, Rossi DJ. "Selective HSC-Ablation Using Anti-CD117 Antibody Drug Conjugate Enables Safe and Effective Autologous and Allogenic Hematopoietic Stem Cell Transplantation." Abstract. Featured Poster. A Czechowicz presented at the 2018 International Society of Experimental Hematology (ISEH), Los Angeles, CA (8/25/2018).
3. Kraft D, Walck E, Carrasco A, Crocker M, Song L, Long M, Najjar S, Nadeem E, Imanbyev G, Mosse M, **Czechowicz A**, McCullough M. "The MarrowMiner: A Novel, Safe, Effective, and Minimally Invasive Device for the Harvest of Bone Marrow Cells." Late-Breaking Abstract Poster. E Walck and D Kraft presented at the 2019 Transplantation and Cellular Therapy (TCT) Meetings, Houston, TX (2/23/2019).
4. Gao C, Schroeder JA, Xue F, Jing W, Subramaniam S, Weiler H, **Czechowicz A**, Shi Q. "Using non-genotoxic, antibody-drug-conjugate conditioning enables safe and effective platelet-specific FVIII gene therapy of hemophilia A." Abstract Poster. Q Shi presented at the 2019 Congress of International Society on Thrombosis and Haemostasis (ISTH), Melbourne, Australia (7/7/2019).
5. **Czechowicz A**, Rio P, Bueren J, Beard B, Nicoletti E, Schwartz JD, and Soni S. "Changing the Natural History of Fanconi Anemia Complementation Group- Δ with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene Insertion in Human Stem and Progenitor Cells." Abstract Poster. A Czechowicz presented at the 2019 American Society of Hematology (ASH), Orlando, FL (12/8/2019).
6. Bertaina A, Bacchetta R, Lewis D, Grimm P, Shah A, Agarwal R, Conception W, **Czechowicz A**, Bhatia N, Lahiri P, Weinberg K, Parkman R, Porteus M, Roncarolo M. " $\alpha\beta$ T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplantation: A New Platform for Curing Rare and Monogenic Disorders." Abstract. A Bertaina presented at the 2020 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, FL (2/20/2020).
7. Van Hentenryck M, Thongthip S, Stone S, Hwang T, Kristovich K, Velez-Bartolomei F, Lee CU, Chu J, Narla A, Sakamoto K, Glader B, Balasa V, Rao L, Agarwal R, Weinberg K, Bertaina A, **Czechowicz A**. "Treatment Resistance in a Fanconi Anemia Mosaic Patient with Myelodysplastic Syndrome." Abstract. M Van Hentenryck presented virtually at the 2020 Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Held online (9/15/2020).

8. Agarwal R, Weinberg K, Kwon H, Le A, Long-Boyle J, Kohn D, Bradford K, De Oliveira S, Bertaina A, **Czechowicz A**, Porteus M, Shyr D, Weinacht K, Shah A, Mavers M, Merkel M, Brown J, Dvorak C, Parkman R, Roncarolo M, Shizuru J. “First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency.” Abstract. R Agarwal presented virtually at the 2020 American Society of Hematology (ASH) Annual Meeting, Held online (12/5/2020).
9. R Agarwal, CC Dvorak, TB Moore, K Weinberg, HS Kwon, J Long-Boyle, A Le, K Truong, D Kohn, K Bradford, S de Oliveira, A Bertaina, **A Czechowicz**, M Porteus, A Shah, D Shyr, K Weinacht, M Mavers, E Merkel, A Vargas, N Harada, JW Brown, WW Pang, R Parkman, MG Roncarolo, JA Shizuru. “Non-Genotoxic Anti-CD117 Transplant Conditioning in Infants with Newly Diagnosed Severe Combined Immune Deficiency.” Abstract. J Shizuru presented virtually at the 2021 Transplantation and Cellular Therapy (TCT) Meeting of ASTCT and CIBMTR, Held online (2/8/2021).
10. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Rio P, Navarro S, Ancliff P, Beard B, Law K, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Rao G, Wagner J, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia [Group A]: Preliminary Results of Ongoing RP-L102 Clinical Trials,” Abstract. A Czechowicz presented virtually at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Held online (5/11/2021).
11. Nofal R, Chan Y, Sen S, Hoang H, Thongthip S, **Czechowicz A**. “Development of A Toolbox of Research Studies for Fanconi Anemia.” Abstract. R Nofal presented virtually at the 4th Annual Stanford Maternal and Child Health Research Institute (MCHRI) Symposium, Held online (10/28/2021).
12. **Czechowicz A**, Sevilla J, Agarwal R, Booth C, Zubicaray J, Río P, Navarro S, Ancliff P, Sebastian E, Choi G, Zeini M, Duran-Persson C, Nicoletti E, Wagner J, Rao G, Thrasher A, Schwartz J, Bueren J, Roncarolo M. “Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2021 American Society of Hematology (ASH) Annual Meeting, Atlanta, GA (12/13/2021).
13. Bubb Q, Cheung C, Seir G, Swartzrock L, Richards R, Mackall C, **Czechowicz A**. “Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia.” Abstract. Q Bubb presented at the 2022 National Comprehensive Cancer Network (NCCN) Annual Conference, Held online (3/31/2022).
14. Chan Y, Nofal R, Ho P, Thongthip S, Rayburn M, Swartzrock L, Scheck A, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Abstract. A Czechowicz presented at the 2022 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Salt Lake City, UT (4/24/2022).

15. Chan Y, Nofal R, Ho P, Thongthip S, Rayburn M, Swartzrock L, Scheck A, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Abstract. A Czechowicz presented at the 2022 Joint ASTCT – EBMT Basic and Translational Scientific Retreat, Vail, CO (5/25/2022).
16. Chan Y, Nofal R, Ho P, Thongthip S, Rayburn M, Swartzrock L, Scheck A, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.” Abstract. A Czechowicz presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, San Francisco, CA (6/15/2022).
17. Chan Y, Nofal R, Ho P, Swartzrock L, Rayburn M, Nofal R, Thongthip S, Weinberg K, **Czechowicz A**. “Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia Mice through Antibody-Mediated Hematopoietic Stem Cell Transplantation.” Abstract. A Czechowicz presented at the 2022 American Society of Hematology (ASH), New Orleans, LA (12/11/2022).
18. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Wagner JE, Rao G, Thrasher A, Schwartz J, Roncarolo M, Bueren J. “Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials.” Abstract. A Czechowicz presented at the 2022 American Society of Hematology (ASH), New Orleans, LA (12/12/2022).
19. Kunte N, Din H, Saina G, Istomina E, Dougall K, MacDonald B, Bartolome R, Olsen A, Bouge A, **Czechowicz A**, Agarwal R, Porteus M. “Implementation of a Phase 1b/2a Clinical Trial for Fanconi Anemia Patients Using JSP191 Antibody Conditioning and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Grafts: A Center Experience.” Abstract. N Kunte presented at the 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, FL (2/16/2023).
20. Agarwal R, **Czechowicz A**, Felber M, Klinger E, Saini G, Kunte N, Nofal R, Weinacht K, Klein O, Shyr D, Weinberg K, Roncarolo M, Bertaina A. “TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Haploidentical Stem Cell Transplantation for Fanconi Anemia: The Stanford Children’s Experience” Abstract. A Czechowicz presented at the 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, FL (2/16/2023).
21. Agarwal R, Bertaina A, Nofal R, Saina G, Kunte N, Sen S, Chan Y, Willner H, Felber M, Krampf M, Van Hentenryck M, Walck E, Scheck A, Thongthip S, Logan A, Dougall K, Bouge A, Boelens JJ, Long-Boyle J, Parkman R, Weissman I, Shizuru J, Pang W, Roncarolo M, Porteus M, **Czechowicz A**. “Initial Results from Stanford Children’s Fanconi Anemia Clinical Trial Using JSP191 Antibody Conditioning and TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Grafts.” Abstract. R Agarwal presented at the 2023 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, FL (2/16/2023).

22. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Choi G, Zeini M, Nicoletti E, Wagner JE, Eide C, Rao G, Thrasher A, Schwartz J, Roncarolo M, Bueren J. "Lentiviral-mediated Gene Therapy for Fanconi Anemia [Group A]: Results from RP-L102 Clinical Trials." Abstract. A Czechowicz presented at the 2022 American Society of Pediatric Hematology and Oncology (ASPHO), Fort Worth, TX (5/12/2023). *Selected for poster highlight* (5/10/23).
23. **Czechowicz A**, Sevilla J, Booth C, Agarwal R, Zubicaray J, Río P, Navarro S, Chetty K, O'Toole G, Xu-Bayford J, Ancliff P, Sebastián E, Rothe M, Bastone AL, John-Neek P, Schambach A, Wang W, Choi G, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao G, Thrasher A, Schwartz JD, Roncarolo MG, Bueren JA. "Lentiviral-mediated Gene Therapy (RL-L102) for Fanconi Anemia [Group A] is Associated with Polyclonal Integration Pattern in Absence of Conditioning." Abstract. A Czechowicz presented at the 2024 Fanconi Cancer Foundation (FCF) Scientific Symposium, Charlotte, NC (9/19/2024).
24. Valine L, Kensinger S, Prentiss K, Agarwal A, **Czechowicz A**, John T, Alexander J, Tsai J, Wang W, Li Y, Weinberg K. "Hematopoietic Stem and Progenitor Cell (HSPC) Frequencies and Clonogenicity in Fanconi Anemia as an Endpoint for Clinical Trials to Prevent Marrow Failure." Abstract. L Valine presented at the 2024 Fanconi Cancer Foundation (FCF) Scientific Symposium, Charlotte, NC (9/21/2024).
25. Soco C, Krampf M, Chan YY, Hoang H, Kunte N, Saini G, Weinberg K, Parkman R, Agarwal R, Bertaina A, Porteus M, **Czechowicz A**. "Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCR $\alpha\beta$ ⁺ T-Cell/CD19⁺ B-Cell Depleted Haploidentical Grafts." C Soco presented at the 2024 American Society of Hematology (ASH) Annual Meeting, San Diego, CA (12/7/2024).
26. Swartzrock L, Pan W, Krampf M, Hoang H, Denis M, Cool T, Ho K, Steele M, Brown B, Han J, MacKenzie TC, **Czechowicz A**. "Robust Immune Reconstitution in Fanconi Anemia Mice Post in Utero Hematopoietic Stem Cell Transplantation." Abstract. L Swartzrock presented at the 2024 American Society of Hematology (ASH) Annual Meeting, San Diego, CA (12/9/2024).
27. Chan YY, Ho PY, Dib C, Swartzrock L, Rayburn M, Willner H, Ethan K, Denis M, Cool T, **Czechowicz A**. "Targeted Hematopoietic Stem Cell Depletion Through SCF-Blockade." A Czechowicz presented at the 2025 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Honolulu, HI (2/13/2025).
28. Dib C, Queenan JA, Willner H, Swartzrock L, Charlesworth C, Denis M, Davis JR, Naukauchi H, Liu DR, **Czechowicz A**. "Combining HSC Base-Editing With Anti-CD117 Antibody Conditioning to Correct Severe Combined Immunodeficiency Disorder in A Novel Mouse Model." A Czechowicz presented at the 2025 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Honolulu, HI (2/13/2025).
29. Swartzrock L, Krampf M, Ho K, Willner H, Iliopoulou B, Meyer E, **Czechowicz A**. "Immunomodulatory Conditioning Alone Enables Haploidentical Stem Cell Transplantation in Mice." Abstract. A Czechowicz deferred presentation at the 2025 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Honolulu, HI (2/13/2025).

30. Seir G, Bubb QR, Salzman G, **Czechowicz A**, Zhang TY, Kennedy VE. “Single-Cell and Bulk RNA Sequencing Analysis of Adult Patients with Acute Myeloid Leukemia to Identify Potential for Transferability of Pediatric Trivalent CAR-T Approaches.” G Seir presented at the 2025 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Honolulu, HI (2/13/2025).
31. Boonchalermvichian C, Yan H, Baker J, Bubb QR, Gupta B, **Czechowicz A**, Negrin R. “Engineered Invariant Natural Killer T Cells (iNKT cells) Targeting CD117 As a Novel Treatment for Acute Myeloid Leukemia.” Abstract. C Boonchalermvichian presented at the 2025 Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Honolulu, HI (2/13/2025).
32. Agarwal R*, Bertaina A*, Soco C, Long-Boyle JR, Saini G, Kunte N, Hiroshima L, Chan YY, Willner H, Krampf M, Nofal R, Barbarito G, Sen S, Van Hentenryck M, Walck E, Scheck A, Perriman R, Bouge A, Istomina E, Din H, Klinger EF, Cheng JC, Wlodarski MW, Boelens JJ, Shizuru J, Pang WW, Weinberg K, Parkman R, Roncarolo MG, Porteus M*, **Czechowicz A***. “Haploidentical Transplant Experience for Patients with Fanconi Anemia – Elimination of Irradiation and Busulfan from the Conditioning Regimen.” Abstract. R Agarwal presented at the 2025 Fanconi Cancer Foundation (FCF) Scientific Symposium, Minneapolis, MN (9/25/2025).
33. **Czechowicz A**, Sevilla J, Booth C, Zubicaray J, Río P, Navarro S, Chetty K, Xu-Bayford J, Ancliff P, Sebastián E, Rothe M, Bastone AL, John-Neek P, Schambach A, Zeini M, Nicoletti E, Eide C, Wagner JE, Rao GR, Thrasher AJ, Schwartz JD, Roncarolo MG, Bueren JA, Agarwal R. “Updated Results from a Global Clinical Trial of RP-L102, a Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group A].” Abstract. A Czechowicz presented at the 2025 Fanconi Cancer Foundation (FCF) Scientific Symposium, Minneapolis, MN (9/25/2025).
34. Queenan JA*, Dib C*, Swartzrock L, Willner H, Denis M, Ahmed N, Moulana Zada F, Borges B, Charlesworth CT, Lum T, Yates BP, Kwon C, Scorzo AV, Davis S, Davies JR, He R, Xie J, Gao G, MacKenzie T, Liu DR, Newby GA, **Czechowicz A**. “Illuminating In Vivo Gene Editing Modalities with the GFP-on Model Mouse.” Abstract. JA Queenan presented at the 2025 American Society of Gene and Cell Therapy (ASGCT) Breakthroughs in Targeted In Vivo Gene Editing Meeting, San Diego, CA (11/20/2025).
35. Agarwal R, Bertaina A, Soco C, Long-Boyle JR, Saini G, Kunte N, Hiroshima L, Chan YY, Willner H, Krampf M, Van Hentenryck M, Perriman R, Istomina E, Barbarito G, Scheck A, Din H, Klinger E, Cheng JC, Wlodarski MW, Boelens JJ, Shizuru J, Pang W, Weinberg K, Parkman R, Roncarolo MG, Porteus M*, **Czechowicz A***. “Hematopoietic Stem Cell Transplantation Using Briquilimab (Anti-CD117 Antibody- Conditioning), Immunosuppression and TCR $\alpha\beta$ + T-cell/CD19+ B-cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia: An Approach without Irradiation, Busulfan and Calcineurin Inhibitors.” Abstract. A Czechowicz presented at the 2025 American Society of Hematology (ASH) Annual Meeting, Orlando, FL (12/6/2025).

36. Ali M, Joseph C, Xu X, Gaskin D, Kabore D, Mukendi JPK, Idowu A Hegazy AM, Scheck A, **Czechowicz A**, Fitzhugh C. “Non-Genotoxic Conditioning to Increase Donor Chimerism Levels in a Mismatched Murine Transplant Model for Sickle Cell Disease.” Abstract. M Ali presented at the 2025 American Society of Hematology (ASH) Annual Meeting, Orlando, FL (12/8/2025).

VII. GRANTS AND FUNDED PROJECTS

Current Funding

- 9/2018 – present **Stanford Lorry Lokey Faculty Scholar**
Project Title: “Faculty Scholar Award.”
Role: Principal Investigator.
- 9/2018 – present **Lorry I. Lokey Philanthropic Gift**
Project Title: “The Lorry I. Lokey Center for Definitive and Curative Medicine Research Fund.”
Role: Co-Investigator. PI: Initially M.G. Roncarolo, now M. Porteus. *[Established relationship with philanthropic donor and spearheaded efforts to support clinical research studies in Fanconi Anemia.]*
- 9/2019 – present **Ludwig Center for Cancer Stem Cell Research and Medicine**
Project Title: “Research Support Award.”
Role: Principal Investigator.
- 6/2020 – 12/2026 **Rocket Pharmaceuticals, Ltd. Sponsored Research Agreement**
Project Title: “Master Collaboration Agreement: FANCA exploratory studies.”
Role: Principal Investigator.
- 9/2020 – present **Thomas and Joann Prescott Philanthropic Gift**
Project Title: “The Bone Marrow Failure Fund.”
Role: Principal Investigator.
- 3/2023 – 4/2026 **Fanconi Cancer Foundation**
Project Title: “Development of In Utero Therapies for Fanconi Anemia.”
Role: Principal Investigator.
- 6/2023 – 5/2027 **California Institute of Regenerative Medicine -- CLIN2**
Project Title: “Reduced Intensity Conditioning with JSP191 Prior to TCRab+ T-cell/CD19+ B-cell Depleted Hematopoietic Stem Cell Transplant for Fanconi Anemia Patients.” PI: M. Porteus.
Role: Co-Investigator. *[Conceptualized clinical trial research study, and spearheaded development and execution of the work. Initiated and contributed to all aspects of grant writing that led to this substantial grant. Elected to not be PI to minimize liability on trial and conflicts of interest with Jasper Therapeutics who provided study drug.]*

- 9/2023 – present **Kindness Over Muscular Dystrophy Foundation**
 Project Title: “Curran DMD Research Fund.”
 Role: Principal Investigator.
- 12/2023 – 11/2026 **Falk Medical Research Trust Catalyst Award**
 Project Title: “Development of Novel DNA-guided Argonaute Base Editing.”
 Role: Principal Investigator.
- 7/2024 – 6/2026 **Diamond Blackfan Anemia Foundation**
 Project Title: “Development of Non-Genotoxic Anti-c-KIT Antibody-Based Conditioning for Hematopoietic Stem Cell Transplantation in DBA.”
 Role: Principal Investigator, with co-PI K. Sakamoto (Stanford).
- 1/2025 – 12/2026 **Bachrach Family Foundation**
 Project Title: “Secreted Particle Information Transfer (SPIT) – A Novel Platform for Treatment of Genetic Diseases.”
 Role: Principal Investigator, with co-PI H. Nakauchi (Stanford).
- 7/2025 – 7/2026 **Fulcrum Therapeutics Inc, Sponsored Research Agreement**
 Project Title: “Development of Small Molecule Calmodulin Pathway Modulators with Fulcrum Therapeutics Inc.”
 Role: Principal Investigator.
- 7/2025 – present **Anonymous Donor**
 Project Title: “The Czechowicz Lab Research Fund.”
 Role: Principal Investigator.
- 8/2025 – 7/2026 **American Society of Hematology (ASH) Bridge Grant**
 Project Title: “Understanding HSC Protection in Bone Marrow Conditioning.”
 Role: Principal Investigator.
- 9/2025 – 8/2026 **Translational Research and Applied Medicine (TRAM) Pilot Grant**
 Project Title: “Spatial Analysis of Hematopoietic Stem Cell Protection Dynamics Throughout Bone Marrow Conditioning.”
 Role: co-Principal Investigator, with PI A. Tan (Postdoctoral Fellow, Stanford).
- 9/2025 – 6/2030 **National Institutes of Health (NHLBI) (1R01HL179280-01)**
 Project Title: “Developing Innovative Cell and Gene Therapy Strategies to Treat Fanconi Anemia.”
 Role: Principal Investigator, with Co-I H. Nakauchi (Stanford).
- 9/2025 – 6/2030 **National Institutes of Health (NHLBI) (2R01HL156647-05)**
 Project Title: “Base Editing and Prime Editing for Sickle Cell Disease.”
 Role: Principal Investigator, with Co-PIs M. Weiss (St. Jude) and D. Liu (Harvard/Broad).

- 10/2025 – 12/2026 **Center for Definitive and Curative Medicine (CDCM)**
 Project Title: “In Utero Hematopoietic Stem Cell Transplantation (IUHSCT) for Fanconi Anemia (FA)”
 Role: Principal Investigator, with Co-PI Y. Blumenfeld (Stanford).
- 1/2026 – 1/2027 **Diamond Blackfan Anemia Foundation**
 Project Title: “Development of Mobilization-Based Conditioning for Hematopoietic Stem Cell Transplantation in DBA.”
 Role: Principal Investigator, with co-PI K. Sakamoto (Stanford).
- 4/2026 – 3/2027 **Sarafan ChEM-H Nucleus Seed Grant**
 Project Title: “Novel DNA-Guided Argonaute Nucleases for Programmable and Multiplexed In Vivo RNA Knockdown.”
 Role: Principal Investigator.

Pending and Submitted Funding

- 7/2025 – 6/2030 **National Institutes of Health (NIDDK) (1R01DK144495-01) – Pending**
 Project Title: “Genome Engineering to Enhance Erythropoiesis for Sickle Cell Disease Therapy.”
 Role: Principal Investigator, with Co-PI K. Cromer (UCSF) and co-Is T. MacKenzie (UCSF) and M. Walters (UCSF).
[Supportive program officer feedback with 16%-ile first time submission score though unclear on funding and encouraged to resubmit. Was not funded prior to end of fiscal year and listed as pending administrative review.]

Completed Funding

- 2008 – 2008 HHMI Research Training Fellowship
- 2008 – 2010 Paul and Daisy Soros Fellowship
- 2008 – 2010 Stanford Medical Scientist Training Program (MSTP)
- 2015 – 2017 NIH T32 training grant, Boston Children’s Hospital
- 8/2018 – 12/2021 Fanconi Anemia Research Fund
 Project Title: “Development of a Safe, Completely Non-Genotoxic Anti-c-Kit (CD117) Antibody-Based Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Fanconi Anemia.”
 Role: Principal Investigator.
- 10/2018 – 9/2020 Rocket Pharmaceuticals, Ltd. Sponsored Research Agreement
 Project Title: “Master Collaboration Agreement for Pre-clinical Studies in Fanconi Anemia.”
 Role: Principal Investigator.

- 10/2018 – 9/2021 Stanford Bio-X Seed Grant
 Project Title: “Generation of Optimized Adeno-Associated Viruses for Hematopoietic Stem Cell Transduction.”
 Role: Principal Investigator, with co-PI M. Kay (Stanford).
- 1/2019 – 12/2019 Pediatric Cancer Research Foundation
 Project Title: “Development of Anti-KIT Antibodies and Immunotoxins as Therapeutics and HSCT Conditioning Agents for Pediatric Acute Myeloid Leukemia.”
 Role: Principal Investigator.
- 5/2019 – 4/2020 Baxter Faculty Scholar, Donald E. and Delia B. Baxter Foundation
 Project Title: “Combination Lentiviral Gene Therapy and Non-Genotoxic Anti-C-kit (CD117) Antibody Based Conditioning for Curative Treatment of Blood and Immune Diseases.”
 Role: Principal Investigator.
- 8/2019 – 7/2023 National Institutes of Health (NIAID) – UG3 (1UG3AI150551)
 Project Title: “Delivery Technologies for In Vivo Genome Editing,”
 PD/PI: E. Chaikof (Beth Israel Deaconess Medical Center).
 Role: Co-Investigator.
- 9/2019 – 4/2025 Anastasia Petropulos and George Georgiopoulos Foundation
 Project Title: “4GN Family Fanconi Anemia Research Fund.”
 Role: Principal Investigator.
- 9/2019 – 8/2025 The Taube Family Fund, Taube Philanthropies Fund
 Project Title: “The Taube Stem Cell Pediatric Cancer Research Fund.”
 Role: Principal Investigator.
- 1/2020 – 12/2020 Stanford Maternal Child and Health Research Institute
 Project Title: “Characterization of Novel Human HSC Cell Surface Receptors.”
 Role: Principal Investigator.
- 1/2020 – 12/2021 Andrew McDonough B+ Foundation
 Project Title: “Anti-KIT Antibodies and Immunotoxins as Therapies and HSCT Conditioning Agents for Pediatric AML.”
 Role: Principal Investigator.
- 3/2020 – 6/2023 National Institutes of Health (NIAID) (2R01AI116698)
 Project Title: “AAV Capsid Engineering for Enhancing Gene Transfer.”
 PI: M. Kay (Stanford).
 Role: Co-Investigator.

- 6/2020 – 5/2024 Gabrielle's Angel Foundation
 Project Title: “Development of Anti-KIT Antibodies and Immunotoxins as Therapeutics and HSCT Conditioning Agents for Pediatric Acute Myeloid Leukemia.”
 Role: Principal Investigator.
- 7/2020 – 6/2022 American Society of Transplantation and Cellular Therapy
 Project Title: “Development of Combination HSC Base-Editing and Non-Genotoxic Antibody Conditioning.”
 Role: Principal Investigator.
- 7/2020 – 6/2022 National Blood Foundation
 Project Title: “Determine Genetic Factors that Regulate Progression to Bone Marrow Failure and Myeloid Neoplasia in Fanconi Anemia.”
 Role: Principal Investigator.
- 7/2020 – 9/2022 National Comprehensive Cancer Network
 Project Title: “Development of Anti-hKIT Chimeric Antigen Receptor T-Cells as a Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agent for Cure of Pediatric Acute Myeloid Leukemia.”
 Role: Principal Investigator.
- 9/2020 – 12/2025 Jasper Therapeutics, Inc.
 Project Title: “Treatment of Fanconi Anemia Patients in Bone Marrow Failure Requiring Allogeneic Transplant with Non-Sibling Donors at Stanford Lucile Packard Children's Hospital.”
 Role: Initially Principal Investigator, later Co-Investigator. PI: M. Porteus. *[Conceptualized clinical trial research study and spearheaded development and execution of the work.]*
- 11/2020 – 9/2023 Bill and Melinda Gate’s Foundation
 Project Title: “Exploitation of Hematopoietic Stem Cells Vulnerabilities to Enable In Vivo Genome-Editing for Correction of Blood and Immune Diseases.”
 Role: Principal Investigator.
- 12/2020 – 12/2023 Hyundai Hope on Wheels
 Project Title: “Development of Anti-KIT Antibodies as Therapeutics and HSCT Conditioning Agents for Pediatric Leukemia.”
 Role: Principal Investigator.
- 9/2021 – 8/2023 Department of Defense (DOD) (W81XWH-21-1-0262)
 Project Title: “Development of Non-Genotoxic Hematopoietic Stem Cell Transplantation Regimens for Fanconi Anemia.”
 Role: Principal Investigator.

- 9/2021 – 8/2023 Dunlevie Maternal-Fetal Medicine Center
Project Title: “In-Utero Therapies for Fanconi Anemia.”
Role: Principal Investigator.
- 10/2021 – 9/2022 Sophie's Neighborhood
Project Title: “Single Cell Transcriptomic Assessment of Multicentric Carpometatarsal Osteolysis (MCTO) Patient Samples.”
Role: Principal Investigator.
- 1/2022 – 11/2023 STRM.Bio, Sponsored Research Agreement
Project Title: “Megakaryocyte-Derived Extracellular Vesicles as Delivery Vehicles for Fanconi Anemia Targeted Gene Therapy.”
Role: Principal Investigator.
- 8/2023 – 7/2025 CURE Childhood Cancer
Project Title: “Development of Receptor Tyrosine Kinase-Targeting Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia.”
Role: Principal Investigator.
- 8/2023 – 8/2025 American Society of Hematology Junior Faculty Scholar Award
Project Title: “Clonal Evolution in Patients with Fanconi Anemia.”
Role: Principal Investigator.

VIII. CLINICAL TRIALS

A. Clinical Trials with Leading Active Role

- 1/2019-11/2024 A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34 Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A (GENE TRANSFER) (BMT 335). Trial Registration: NCT03814408. Sponsor: Rocket Pharmaceuticals. PI: R. Agarwal. Role: Prior Principal Investigator (2019-2021), now transitioned to Associate Investigator (2022-2024). *[Lead investigator on this U.S. based clinical trial, contributed to writing trial, and treated all patients on this trial with follow-up during COVID-19 pandemic which required intensive advocacy. Additionally, PI on corollary studies associated with this clinical trial.]*
- 2/2020 – present A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A (GENE TRANSFER) (BMT 360). Trial Registration: NCT04248439. Sponsor: Rocket Pharmaceuticals. PI: R. Agarwal. Role: Prior Principal Investigator (2020-2021), now transitioned to Associate Investigator (2022-present). *[Lead investigator on this global clinical trial, contributed to writing trial, treated majority of patients on this trial with initial patients treated during COVID-19 pandemic which required intensive*

advocacy. Additionally, PI on corollary studies associated with this clinical trial. Biologics license application (BLA) was in evaluation by FDA for pending approval though withdrawn by Sponsor due to corporate funding needs, delayed publication of first-author Nat Med manuscript (In preparation).]

- 3/2021 – present A Phase Ib/IIa Clinical Trial to Evaluate Use of TCR $\alpha\beta$ ⁺ T-cell/CD19⁺ B-cell Depleted Hematopoietic Grafts and a Reduced-Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients with Fanconi Anemia (BMT 373). Trial Registration: NCT04784052. Sponsor: M. Porteus, previously M. G. Roncarolo. PI: R. Agarwal. Role: Prior Principal Investigator (2021), now transitioned to Associate Investigator (2022-present). Initiated this Investigator Initiated Trial (IIT). *[Conceptualized clinical trial, wrote entire protocol, and enabled clinical trial through obtaining initial philanthropic and subsequent CIRM grant funding. Laboratory also performing critical corollary studies. Phase 1b completed, Phase 2a on-going with full trial enrollment and patient treatments completed as of 7/2025. FDA and IRB amended 10/2025 to treat an additional group of patients to further innovate and improve upon this clinical protocol. Co-senior author and corresponding author manuscript published in Nat Med 9/2025.]*
- 11/2021 – present Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102 (GENE TRANSFER) (BMT384 Rocket LTFU). Sponsor: Rocket Pharmaceuticals. PI: R. Agarwal. Role: Associate Investigator. *[Initiated studies with patient accrual from Phase 1 and Phase 2 trials. PI on corollary studies associated with this clinical trial.]*
- 5/2024 – present In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses with Fanconi Anemia. Trial Registration: NCT07408583. Role: Sponsor. PI: Y. Blumenfeld. Status: IND approved and in study initiation. *[Conceptualized clinical trial based upon independent pre-clinical data, obtained support from multi-disciplinary colleagues across various institution with dedicated workshop discussion, wrote clinical protocol and filed IND 11/2025 with approval to proceed 12/2025.]*
- 8/2025 – present A Phase 1/2, Open-label, Single-arm Study of APR-2020 in Transfusion-dependent, Steroid-resistant Pediatric and Adolescent Subjects with RPS19 deficient Diamond-Blackfan Anemia by Transplantation of Autologous CD34⁺ Stem Cells Transduced with CLIN-LV-EFS-coRPS19-PRE* (APR-2020). Trial Registration: NCT07476183. Role: Research Investigator. PI: J. Alexander. Sponsor: Apriligen, Inc. Status: IND approved and in study initiation. *[Conceptualized clinical trial design based upon independent pre-clinical data, initiated collaboration with Stanford to become a clinical site, and actively determining correlative studies.]*

B. Additional Clinical Trial Effort

- 4/2018 – 6/2023 An Expanded Access Study Using the CliniMACS System to Offer Therapeutic Manipulated Grafts that are CD34 Cell Enriched and T Cell Depleted for Allogeneic Stem Cell Recipients (BMT 271). Sponsor: R. Agarwal. PI: R. Agarwal. Role: Investigator.
- 9/2019 – present Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34 Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKD. (GENE TRANSFER) (BMT 355). Sponsor: Rocket Pharmaceuticals. PI: A. Shah. Role: Investigator.
- 11/2020 – present Phase 1a/1b Study of T-allo10 Infusion after HLA-Partially Matched Related or Unrelated TCR $\alpha\beta^+$ T-cell/CD19 $^+$ B-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation ($\alpha\beta^+$ depleted-HSCT) in Children and Young Adults Affected by Hematologic Malignancies (BMT 367). Sponsor: M.G. Roncarolo. PI: A. Bertaina. Role: Investigator.
- 2/2023 – present Long-Term Follow-up: Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34 Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKD. (GENE TRANSFER) (BMT 395). Sponsor: Rocket Pharmaceuticals. PI: A. Shah. Role: Investigator.

C. Data Safety Monitor Board (DSMB)

- 5/2020 – 12/2024 In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM). Sponsor: Tippi Mackenzie. Role: Member.

IX. PATENTS:

Patents Granted To-Date: 6 Total, Patents Pending (in Evaluation): 6 Total

Applications Submitted Since Faculty Appointment in 2018: 7 Total

‡ Applications with Primary Role in Writing and Filing: 6 Total

1. Weissman IL, **Czechowicz A**‡, Bhattacharya D, Kraft D: “Immunodepletion of Host Bone Marrow for Improved Engraftment in Stem Cell Niche.” Provisional Patent Filed 11/3/2006, International Patent Filed 11/2/2007, Patent Granted 9/11/2018.
2. Glucksmann A, Palestrant D, Tartaglia L, Mata-Fink J, **Czechowicz A**: “CRISPR-related Methods and Compositions.” US Patent Filed 9/27/2013, International Patent Filed 9/26/2014, Published 8/18/2016.
3. Glucksmann A, Palestrant D, Tartaglia L, Mata-Fink J, **Czechowicz A**, Borisy A: “CRISPR-Related Methods and Compositions with Governing gRNAs.” US Patent Filed 11/7/2013, International Patent Filed 11/7/2014, Published 8/20/2015, Patent Granted 12/5/2017.

4. Scadden D, Palchaudhuri R, Rossi D, **Czechowicz A**‡: “Composition and Methods for Non-Myeloablative Conditioning.” US Patent Filed 4/6/2016, Published 11/29/2018, Patent Granted 2/2/2021.
5. Edge A, Venuti M, **Czechowicz A**: "Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof." US Patent Filed 1/27/2017, Published 1/10/2019, Patent Granted 10/22/2022.
6. Rossi DJ, **Czechowicz A**‡, Murphy PM, Li Z: “Antibody-Mediated Conditioning with Immunosuppression to Enable Allogeneic Transplantation.” US Patent Filed 3/29/2018, Published 6/18/2018.
7. Agarwal R, Long Boyle J, Cowan M, Dvorak C, Kwon H, Le A, Logan A, Pang W, Parkman R, Roncarolo M, Weinberg K, Shizuru J, Prohaska S, **Czechowicz A**, Weissman IL: “Hematopoietic Stem Cell Engraftment.” US Patent Filed 12/7/2018, Published 12/2/2021, Patent Granted 5/9/2023.
8. Weissman IL, **Czechowicz A**‡, Bhattacharya D, Kraft D: “Selective Immunodepletion of Endogenous Stem Cell Niche for Engraftment.” US Patent Filed 12/22/2022, Published 4/27/2023, Patent Granted 2/20/2024.
9. Chan YY, **Czechowicz A**‡: “Use of Immunosuppression to Enable Engraftment of Hematopoietic Stem Cells.” US Patent Filed 1/5/2023, Published 7/13/2023.
10. Huang S, **Czechowicz A**‡: “Peptide Nucleic Acid – Facilitated Argonaute Base Editing.” US Provisional Patent Filed 7/13/2023.
11. Glucksmann A, Palestrant D, Tartaglia L, Mata-Fink J, **Czechowicz A**: “Human Hematopoietic Stem Cell Having a Modified Bcl11a Gene and Methods of Making the Cell.” US Patent Filed 8/16/2023, Published 2/29/2024.
12. Bubb QR, **Czechowicz A**‡, Mackall C, Sotillo E, Richards R, Seir G: “Combinatorial Approaches for Targeting Hematopoietic Cells.” US Patent Filed 4/7/2025.

X. EDITORIAL SERVICE - Ad Hoc Journal Reviewer

2017 – 2018	Current Cancer Drug Targets
2018	Blood
2020	Plos ONE
2020	Human Gene Therapy
2020 – 2021	Journal of Clinical Immunology
2021	Experimental and Molecular Pathology
2022	Blood, American Society of Hematology (ASH) Education Program
2024 – 2025	Bioessays
2025	Molecular Therapy
2025	Frontiers, Frontiers in Pharmacology (Research Topic Editor)
2025	Blood
2025	Blood Advances
2025	Expert Review of Hematology
2025 – 2026	Nature
2025 – 2026	HemaSphere, European Hematology Association (EHA)
2026	Transplantation and Cellular Therapy (TCT)

XI. GRANT REVIEWER SERVICE

2017	Reviewer, Stanford SPARK Program
2018	Poster Reviewer, American Society for Gene and Cell Therapy (ASGCT)
2019	Reviewer, NIH Molecular and Cellular Hematology (MCH) Study Section
2019	Reviewer, Fanconi Anemia Research Fund (FARF)
2021	Reviewer, Great Ormond Street Hospital (GOSH) Children's Charity
2021	Abstract Reviewer, American Society of Transplantation and Cell Therapy
2021	Abstract Reviewer, European Society for Blood and Marrow Transplantation
2023	Abstract Reviewer, Fanconi Anemia Research Fund (FARF)
2024	Abstract Reviewer, Fanconi Cancer Foundation (FCF)
2024	Reviewer - Bone Marrow Failure Research Program (BMFRP) TT Panel, Congressionally Directed Medical Research Programs (CDMRP), Department of Defense (DOD)
2025	Abstract Reviewer, Fanconi Cancer Foundation (FCF)
2025	Abstract Reviewer, European Society for Blood and Marrow Transplant (EBMT)
2025	Invited Reviewer, TAG - Therapeutic Approaches to Genetic Diseases Study Section, National Institutes of Health (NIH) (Scheduled for 11/2025 though due to government closure rescheduled for 1/2026)
2026	Abstract Reviewer, European Society for Blood and Marrow Transplant (EBMT)
2026	Invited Reviewer, BBHV - Basic Biology of Blood, Heart, and Vasculature Study Section, National Institutes of Health (NIH) (Scheduled for 4/2026)

XII. UNIVERSITY ADMINISTRATIVE SERVICE

A. Committee Service

2006 – 2007	Medical School Admissions Student Recruitment Chair, Stanford University
2008 – 2009	Student Representative, Stanford University Faculty Senate
2010 – 2011	Student Member, Stanford School of Medicine Faculty Senate
2010 – 2011	Medical School Representative, Stanford Executive Presidents' Council
2011	Student Member, Committee on Curriculum and Academic Performance
2011	Student Member, MSTP Taskforce
2011	Student Member, Think Tank on Refining Medical Education
2011 – 2012	Student Representative, Stanford University Board of Trustees
2018 – present	Admissions Committee Member for Stanford Graduate School Programs, Stanford MSTP and Stanford Biosciences (Immunology and Stem Cell Biology and Regenerative Medicine); and Interviewer for Stanford Translational Investigator Program (TIP)
2021	Junior Faculty Committee, Stanford LCME Institution Review

B. Leadership Roles

2007 – 2009	Class President, Stanford Medical Student Association
2007 – 2008	Co-President, Transplant Interest Group, Stanford School of Medicine
2008 – 2011	Co-President, Hematology/Oncology Interest Group, Stanford School of Medicine

2009 – 2010	Student Body President, Stanford Medical Student Association
2010 – 2011	Student Body Executive President, Stanford Medical Student Association
2019 – present	Co-Lead, Blood Stem Cell Engineering & Transplantation Platform, Stanford Center for Definitive and Curative Medicine
2020 – present	Associate Director of Graduate Studies, Stem Cell Biology and Regenerative Medicine Graduate Student Program

C. Education and Mentorship

2004 – 2005	BioBridge Counselor, Stanford Biological Sciences Department
2006 – 2008	BioBridge Graduate Mentor, Stanford Biological Sciences Department
2007	Stanford Medical Youth Science Program Graduate Mentor, Stanford University
2007 – 2008	Teaching Assistant, Cells to Tissues (INDE 221), Stanford University School of Medicine
2007 – 2009	Teaching Assistant, Pediatric Chronic Disease (PEDS 281), Stanford University School of Medicine
2008	Group Leader, Stanford Wilderness Experience Activity Trip, Stanford University School of Medicine
2016	Lecturer, Various HMS Courses, Harvard Medical School
2018 – present	Lecturer, Various M.D., Ph.D. and Postdoctoral Courses, Stanford University School of Medicine: IMMUNOL 209, PEDS227, PEDS 255, PATH290, RADO204, STEMREM 200 and STEMREM 203
2018 – present	Lecturer, Various Residency, Fellowship, Nursing and Administrator seminars, Stanford Children's, Lucile Packard Children's Hospital Stanford
2018 – present	Member and Chair for Various Graduate Student Qualifying and Thesis Committees. <i>[Past Stanford Students: 1) Daniel Wesche-Ph.D., 2) Harsh Shah- M.S., 3) Heather Talbott-Ph.D., 4) William Feist-Ph.D., and 5) Quenton Bubb- MSTP. Current Stanford Students: 6) Andrew Burden-Ph.D., 7) Jeremy Bjelajac- Ph.D., 8) Archana Shankar-Ph.D., 9) Aaron Tan-Ph.D., 10) J.K. Gopakumar- MSTP, 11) Anthony Francois-Ph.D., 12) Emma Heaton-Ph.D., 13) Omair Khain-MSTP, 14) Julie Sanchez-Ph.D., 15) Christopher Shiprack-Ph.D., 16) Allison Banuelos-Ph.D., 17) Sarah Rockwood-MSTP, 18) Maria Korah-Ph.D. and 19) Lyn Portillo-Ph.D. Current UCSF Student: 1) Rebecca Chu-Ph.D.]</i>
2018 – present	Mentor, Stanford Women Association of Physician Scientists (SWAPS) M.D./Ph.D. Mentorship Program. <i>[Past Mentees: 1) Dani Zhao, 2) Liana Bonanno, 3) Amira Barkal, 4) Adele Xu, 5) Maria Filsinger and 6) Theodora Bruun. Current Mentees: 7) Preksha Bhagchandani, 8) Samantha Scharenberg, 9) Kylie Burdsall, 10) Shreya Malhotra, 11) Sarah Rockwood, 12) Maggie Chen, 13) Sabrina Bond and 14) Daria Azizad.]</i>
2018 – present	Mentor, California Institute of Regenerative Medicine (CIRM) Stem Cell Internship in Laboratory-based Learning (SCILL) Bridges Program through San Jose State University and California State Polytechnic University-Humboldt. <i>[Past Mentees: 1) Tenzin Dolma Shakya, 2) William Zhang, 3) Hana Hoang, 4) Sushmita Sen, 5) Suzan Stavitsky, 6) Dalila Cardenas, and 7) Loowyza Colegrove. Current Mentee: 8) Biann Shehadeh.]</i>

2018 – present	Mentor, Stanford Pediatrics Internship Program (PIPS) and other local high school students. [<i>Past Mentees: 1) Aavani Sree, 2) Ethan Ko, 3) Quetzalli Hernandez, 4) Joline Mai, and 5) Jack Flynn.</i>]
2019 – present	Mentor, Stanford 1 st Generation Medical Student Mentorship Program
2020 – present	Mentor, Stanford Stem Biology Ph.D. First Year Mentorship Program
2020 – present	Course Director and Instructor, IMMUNOL 223: Biology and Disease of Hematopoiesis. [<i>Student requested course; with undergraduate, graduate and medical student enrollment.</i>]
2021 – present	Mentor, Stanford MSTP BOOST and Stanford ADVANCE Undergraduate Institute and give annual lecture with Stanford EXPLORE program
2021	Group Faculty Mentor, Stanford Pediatrics Fellows Scholarship Academy
2023 – present	Faculty Mentor and Lecturer, Stanford Hematology R25
2023 – present	Faculty Mentor, Stanford <u>L</u> earners to <u>l</u> eaders in <u>U</u> rology, <u>N</u> ephrology, and non- <u>C</u> ancer <u>H</u> ematology (LAUNCH) TL1 Training Program
2023 – present	Decades Mentor, Paul & Daisy Soros Fellowship for New Americans
2024	Stanford Medical School Discovery Day in Fireside Chat Panel
2024 – present	University of Florida T32 Advisory Committee for Cell and Gene Therapy

XIII. PROFESSIONAL ORGANIZATION SERVICE

A. Membership

2006 – present	American Medical Association (AMA)
2008 – present	American Society of Hematology (ASH)
2009 – present	International Society for Stem Cell Research (ISSCR), Special Invited Nucleus Forum Member (2018- present)
2010 – present	American Society of Bone Marrow Transplantation (ASBMT)
2013 – present	American Society of Gene and Cell Therapy (ASGCT)
2018 – present	American Society for Transplantation and Cellular Therapy (ASTCT)
2019 – present	International Society Cell & Gene Therapy (ISCT)
2020 – present	International Society for Experimental Hematology (ISEH)
2022 – present	American Society for Transplantation (AST)

B. Committee Service

2010 – 2012	International Society for Stem Cell Research (ISSCR): Junior Investigator Committee
2020 – present	American Society for Transplantation and Cellular Therapy (ASTCT): Talent Acquisition Task Force
2021 – present	Fanconi Anemia Clinical Care: Guidelines Consensus Committee (FACCGCC)
2022 – present	Fanconi Anemia Cancer Consortium (FACC)
2022 – present	American Society for Gene and Cell Therapy (ASGCT): Stem Cell Committee
2022 – present	American Society for Gene and Cell Therapy (ASGCT): Trainee Committee
2023 – present	American Society for Gene and Cell Therapy (ASGCT): Fetal Cell and Gene Therapy Committee (inaugural member)

XIV. INVITED PRESENTATIONS (Since Faculty Appointment Only)

Invited Speaker / Panelist: 15 Local and Regional, 37 National and 36 International

Local and Regional Meetings:

1. Keynote Speaker, California Institute of Regenerative Medicine (CIRM) Bridges Program Graduation, San Jose State University, San Jose, CA (5/3/2018).
"Hematopoietic Stem Cells: A Powerful Platform for The Treatment of Blood and Immune Diseases"
2. Pediatric Grand Rounds Speaker, Harvey J. Cohen Endowed Lectureship in Pediatrics Speaker, Lucile Packard Children's Hospital Stanford, Stanford, CA (1/11/2019).
"Development of Safer Conditioning Strategies for Hematopoietic Stem Cell Transplantation"
3. Seminar Speaker, UC Berkeley - Innovative Genomics Institute (IGI) "SIP" Seminar Series, Held online (5/19/2020).
"Enabling Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation"
4. Panel Speaker, Silicon Valley Poland Days, Science and Technology Symposium, Held online (10/22/2020).
"Medicine and Healthcare"
5. Symposium Speaker, Center for Definitive and Curative Medicine (CDCM) Annual Symposium, Held online (2/25/2021).
"Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation"
6. Panel Speaker, Stanford MSTP AUI/BOOST Program, Held online (4/8/2021).
"Showcasing Your Strengths"
7. Seminar Speaker, Stanford Regenerative Medicine Seminar (ReMS) Series, Held online (11/4/2021).
"Compete or Perish – HSC Dynamics in Fanconi Anemia"
8. Symposium Speaker, Stanford Fetal Therapy: Current Status and Future Directions Symposium, Held online (11/9/2021).
"Stem Cell and Gene Editing Therapies"
9. Panel Speaker, Poland Days in Silicon Valley 2021 – Post-Pandemic Accelerated Digital World, Held online (12/8/2021).
10. Seminar Speaker, California Institute of Regenerative Medicine (CIRM) Bridges Program, San Jose State University (SJSU), Held online (10/31/2022).
"Novel Conditioning Regimens for Hematopoietic Cell Transplantation: Progress Towards Safe, Curative Treatment of Blood and Immune Diseases"
11. Panel Speaker, Stanford Center for Definitive and Curative Medicine Annual Symposium, Stanford, CA (3/13/2024).
"CDCM Translational Success from the Bench to the Bedside – Story of Treating Fanconi Anemia"
12. Symposium Speaker, Stanford Dunlevie Maternal Fetal Medicine Center Fetal Therapy Symposium, Held online (5/2/2024).
"In Utero Transplantation for Fanconi Anemia"
13. Speaker, Stanford Pediatrics & American Red Cross Youth Health Symposium, Stanford, CA (10/11/2025).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"
14. Speaker, Polish Science and Technology Summit, Berkeley, CA (10/11/2025).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"

15. Seminar Speaker, California Institute of Regenerative Medicine (CIRM) Bridges Program, San Jose State University (SJSU), Held online (11/24/2025).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"

National Meetings:

16. Seminar Speaker, National Institutes of Health (NIH), Washington, DC (4/27/2018).
"Discovery of Non-Toxic Conditioning Regimens for Stem Cell Therapies"
17. Seminar Speaker, Blood Center of Wisconsin, Waukesha, WI (11/6/2018).
"Discovery of Non-Toxic Conditioning Regimens for Stem Cell Therapies"
18. Seminar Speaker, Nationwide Children's Hospital, Columbus, OH (11/9/2018).
"Discovery of Non-Toxic Conditioning Regimens for Stem Cell Therapies"
19. Speaker, Fanconi Anemia Family Meeting, Camp Sunshine, Casco, ME (6/23/2019).
"Update on U.S. Gene Therapy Trial for FA"
20. Speaker, Arc Fusion Future of Humans Summit, Boston, MA (12/4/2019).
"Future of Blood and Immune Replacement"
21. Speaker, National Institutes of Health (NIH) and Bill & Melinda Gates Foundation (BMGF) Expert Scientific Roundtable Webinar Meeting, Held online (5/11/2020).
"Achieving Selective and Precise In Vivo Targeting and Gene Editing: Key Features of HSCs and Their Environment"
22. Research Speaker, Fanconi Anemia Family Meeting, Camp Sunshine, Held online (6/26/2020).
"Stanford Antibody Conditioning Trial"
23. Clinical Speaker, Fanconi Anemia Family Meeting, Camp Sunshine, Held online (6/29/2020).
"Gene Therapy: Stanford Trial & Rocket Pharmaceuticals, Inc."
24. Grand Rounds Speaker, City of Hope, Held online (11/5/2020).
"Progress Towards Safe, Curative Treatment of Blood and Immune Diseases; Learnings from the Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation"
25. Symposium Speaker, Sickle Cell Transplant Advocacy and Research Alliance (STAR) Annual Meeting, Held online (11/9/2020).
"Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation"
26. Symposium Speaker, Howard Hughes Medical Institute (HHMI), R3 - Replace, Repair, Regenerate Symposium, Held online (7/21/2021).
"Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation"
27. Speaker, Science Polish Perspectives Meetup USA, Held online (9/17/2021).
"Stem Cell Transplantation - Where We Are Now and Where We Hope to Be"
28. Symposium Speaker, University of California- San Diego (UCSD), Sanford Stem Cell Symposium, Held online (10/15/2021).
"Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Learnings from Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation"
29. Seminar Speaker, Memorial Sloan Kettering Cancer Center (MSKCC), Transplant and Cellular Therapy Options for Non-Malignant Hematologic Disorders Symposium, Held online (10/15/2021).
"Individualized Conditioning Regimens: Antibody Based Conditioning"
30. Panel Speaker, Convergence Forum, Harwich, MA (10/29/2021).
"Regenerative Medicine and Stem Cell Therapies"
31. Panel Speaker, STAT Summit, Held online (11/16/2021).
"Breaking Biotech's Barriers"
32. Seminar Speaker, Prime Medicine Science Seminar Series, Held online (11/30/2021).
"Fanconi Anemia: From Disease Biology to Current Treatments"

33. Seminar Speaker, National Heart, Lung and Blood Institute (NHLBI)'s Fellowship Hematology Conference, Held online (1/5/2022).
"Development of New Treatments for Fanconi Anemia: Gene Therapy and Antibody-Based Stem Cell Transplantation"
34. Seminar Speaker, Rome Therapeutics Seminar and Roundtable Discussion, Held online (3/11/2022).
"Fanconi Anemia: From Disease Biology to Current Treatments"
35. Keynote Speaker, William Blair Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Symposium, Held online (9/29/2022).
"Hematopoietic Stem Cell Transplantation/Preconditioning"
36. Seminar Speaker, St. Jude Children's Research Hospital Hematology Research Seminar Series, Held online (10/21/2022).
"Development of Improved Cell and Gene Therapies for Fanconi Anemia and Beyond"
37. Seminar Speaker, Capstan Therapeutics Science Seminar Series, Held online (12/2/2022).
"Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Learnings from the Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation"
38. Research Speaker, Fanconi Anemia Family Meeting, Camp Sunshine, Casco, ME (6/27/2023).
"FA Center of Excellence Presentation - Stanford University"
39. Panel Speaker, Fanconi Anemia Family Meeting, Camp Sunshine, Casco, ME (6/27/2023).
"FA Centers of Excellence"
40. Speaker, National Institute of Health (NIH) Science of Conditioning Workshop, Held online (1/25/2024).
"Earliest Work on CD117 (c-Kit) Antibody Conditioning"
41. Grand Rounds Speaker, Johns Hopkins Hematology Grand Rounds, Held online and live in Baltimore, MD (3/3/2025).
"Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia Disease"
42. Seminar Speaker, Fulcrum Therapeutics Science Seminar Series, Held online and live in Cambridge, MA (3/20/2025).
"Fanconi Anemia: From Disease Biology to Innovative New Treatments"
43. Seminar Speaker, Emory University / Aflac Cancer and Blood Disorders Center Research Seminar, Atlanta, GA (4/1/2025).
"Development and Application of Non-Genotoxic Conditioning and Stem Cell Transplantation to Enable Curative Treatment of Diverse Diseases with a Focus on Fanconi Anemia"
44. Seminar Speaker, St. Jude Children's Research Hospital Hematology Research Seminar Series, Memphis, TN (4/2/2025).
"Development of Improved Cell and Gene Therapies for Fanconi Anemia and Beyond"
45. Seminar Speaker, Cedars-Sinai Research Seminar, Los Angeles, CA (4/3/2025).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"
46. Seminar Speaker, Texas Children's, Houston, TX (4/10/2025).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"
47. Fetal Sequencing Consortium Speaker Series, Women's Genetics Program, Department of Obstetrics and Gynecology, Columbia University, Held online (4/15/2025).
"Innovative Cell and Gene Therapies for Fanconi Anemia – with a Focus on Prenatal Therapy"
48. Fellows Conference, Memorial Sloan Kettering Cancer Center, New York City, NY (4/21/2025).
"Fanconi Anemia: From Disease Biology to Innovative New Treatments"
49. Seminar Speaker, Washington University in St. Louis (WashU), St. Louis, MO (5/19/2025).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"
50. Speaker, American Society of Hematology (ASH) Speakers Series in partnership with the U.S. Food and Drug Administration (FDA), Held online and live in Washington, D.C. (6/11/2025).
"Innovative Non-Genotoxic Gene Therapy for Patients with Fanconi Anemia"

51. Special Seminar Speaker, Joint Hematology/Oncology/BMT Research Conference, University of California – San Francisco (UCSF), San Francisco, CA (7/21/2025).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"
52. Symposium Speaker, Versiti Blood Research Institute Hematopoiesis Symposium on Bone Marrow Failure: From Basic Science to Therapy, Milwaukee, WI (3/19/2026).
"Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia"

International Meetings:

53. Keynote Speaker, British Society of Bone and Marrow Transplantation (BBMT) Annual Meeting, London, England (05/16/2017).
"Development of Antibody-based Conditioning Agents for Transplant: Towards More Targeted Therapy?"
54. Symposium Speaker, Haploidentical Transplantation Symposium (HAPLO2018), San Diego, CA (11/29/2018).
"Development of Anti-CD117 mAb Conditioning Strategies for Hematopoietic Stem Cell Transplantation"
55. Panel Speaker, In Vivo Gene Therapy & Genome Editing Summit, Miami, FL (3/18/2019).
"Novel Therapeutic Targets"
56. Symposium Speaker, Fanconi Anemia Gene Therapy Symposium, South San Francisco, CA (4/19/2019).
"Updates on the Ongoing Clinical Trials in the US"
57. Symposium Speaker, Cord Blood Connect International Congress, Orlando, FL (9/13/2019).
"Novel Conditioning Regimen: Antibody (c-KIT) Conditioning for Non-Malignant Disease"
58. Advisory Board Presenter, CSL Behring, Cell Transplant Board Meeting, Miami, FL (1/17/2020).
"Antibody-Based Strategies"
59. Symposium Speaker, Fanconi Anemia Gene Therapy Symposium, Held online (5/1/2020).
"Updates on the Ongoing Clinical Trials in the U.S."
60. Symposium Speaker, American Society for Gene and Cell Therapy (ASGCT) Annual Meeting, Held online (5/12/2020).
"Improving HSCT Transplantation by Novel Conditioning - How it applies to Allogeneic HSCT"
61. Conference Speaker, World's Definitive Antibody-Drug Conjugate Conference, Held online (9/18/2020).
"Selective Hematopoietic Stem Cell Ablation using CD117-Antibody-Drug-Conjugates Enables Safe and Effective Transplantation with Immunity Preservation"
62. Conference Speaker, International Fetal Immunology and Transplantation Society (IFeTIS) Conference, Held online (10/2/2020).
"In Utero Therapy for Fanconi Anemia"
63. Speaker, World Antibody-Drug Conjugate (ADC) Europe Annual Meeting, Held online (3/10/2021).
"Progress Towards Safe, Curative Treatment of Blood & Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation"
64. Speaker, European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Held online (3/16/2021).
"Antibody-Based Conditioning in SCID and Beyond"
65. Speaker, Fanconi Anemia Research Foundation (FARF) Annual Scientific Symposium, Held online (7/8/2021).
"Gene Therapy for Fanconi Anemia: Interim Results from RP-L102 Global Clinical Trials"
66. Speaker, International Symposium on $\alpha\beta$ T-cell/CD19 B-cell depleted Haploidentical Stem Cell Transplantation, Held online (10/20/2021).
" $\alpha\beta$ T-cell/CD19 B-cell Depleted Haploidentical HSCT Combined with Antibody Conditioning Regimen for Fanconi Anemia"

67. Lecturer, Institute of Transfusion Medicine of Goethe University and German Red Cross Blood Service, Held online (11/17/2021).
“Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation”
68. Speaker, CSL Behring, Research Symposium, Held online (4/6/2022).
“Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Antibody Conditioning Regimens for Hematopoietic Cell Transplantation”
69. Speaker, International Society for Stem Cell Research (ISSCR) Annual Meeting, San Francisco, CA (6/14/2022).
“Advancing Hematopoietic Cell Therapies”
70. Speaker, Fanconi Anemia Research Foundation (FARF) Annual Scientific Symposium, Austin, TX (9/11/2022).
“Stanford Children’s Fanconi Anemia Clinical Trial Using JSP191 Antibody Conditioning and TCRαβ+ T-Cell/CD19+ B-Cell Depletion”
71. Speaker, Society of Hematologic Oncology (SOHO) Saudi Arabia Annual Meeting, Held online (10/10/2022).
“Gene Therapy for Fanconi Anemia”
72. Speaker, Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Orlando, FL (2/16/2023).
“Transplant Approaches for Bone Marrow Failure Syndromes: Fanconi Anemia”
73. Speaker, North American Pediatric Aplastic Anemia Consortium, Held online (9/18/2023).
“Educational Webinar Series on BMF - Gene Therapy for Fanconi Anemia”
74. Speaker, Fanconi Anemia Research Foundation (FARF) Annual Scientific Symposium, Vancouver, Canada (10/1/2023).
“Lentiviral-Mediated Gene Therapy for Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials”
75. Speaker, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Outstanding New Investigator Talk, Baltimore, MD (5/10/2024).
“Development of Innovative Therapies for Blood and Immune Diseases –With a Focus on Fanconi Anemia”
76. Symposium Speaker, Centre for Stem Cell Research (CSCR), Annual Symposium on Cell and Gene Therapy, Held online and live in Vellore, India (8/1/2024).
“Innovative Non-Genotoxic Cell and Gene Therapies for Fanconi Anemia”
77. Symposium Speaker, Kyowa Kirin Gene and Cell Therapy Symposium, La Jolla, CA (10/17/2024).
“Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia”
78. Speaker, International Fetal Immunology and Transplantation Society (IFeTIS) Conference, Wake Forest, NC (11/2/2024).
“Innovative in Utero Therapies for Fanconi Anemia”
79. Speaker, American Society of Hematology (ASH) Annual Meeting, Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure, San Diego, CA (12/6/2024).
“Reduced-Toxicity Hematopoietic Stem Cell Therapies for Fanconi Anemia”
80. Speaker, Tandem Meetings of ASTCT and CIBMTR, Spotlight Session: “Best of Transplantation and Cellular Therapy: Selections from JTCT and New Investigator Awards,” Honolulu, HI (2/13/2025).
“Development of Combination HSC Base-Editing and Non-Genotoxic Antibody-Based Conditioning”
81. Panel Speaker, Health Economics and Outcomes Research (HEOR), FA Consensus Workshop, New York City, NY (3/5-6/2025).
“Clinical Engagement of Defining and Interpreting Response Criteria and Outcomes”

82. Princess Margaret Special Seminar Speaker, Princess Margaret Cancer Centre, University of Toronto, Canada (4/22/2025).
"Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia Disease"
83. Speaker, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Prenatal Gene and Cell Therapy Scientific Session, New Orleans, LA (5/15/2025).
"Unique Biologic Opportunities to Treat Monogenic Blood Disorders Prenatally – In Utero Hematopoietic Stem Cell Therapy Enabling Prenatal Treatment of Fanconi Anemia"
84. Speaker, Annual Academic Conference of the Hematology Branch, Zhejiang Association of Integrative Chinese and Western Medicine, Held online and in Hangzhou City, Zhejiang Province, China (6/7/2025).
"Development of Non-Genotoxic Cell and Gene Therapies for Fanconi Anemia"
85. Speaker, Fanconi Cancer Foundation (FCF) Scientific Symposium, Minneapolis, MN (9/27/2025).
"Development of Prenatal Treatments for Fanconi Anemia"
86. Speaker, 3rd International Congress of the Global Action Network for Sickle Cell and Other Inherited Blood Disorders (GANSID), Held online (11/15/2025).
"Innovative Cell and Gene Therapy Approaches to Improving Outcomes for Patients with Fanconi Anemia"
87. Panelist, 40-year Anniversary of ASH Scholar Awards, American Society of Hematology (ASH) Annual Meeting, Orlando, FL (12/5/2025).
"Clonal Evolution in Patients with Fanconi Anemia"
88. Speaker, American Society of Gene and Cell Therapy (ASGCT) and Alliance for Regenerative Medicine (ARM) AAV Safety: Mechanisms and Risk Mitigation Workshop, Held online and live in Orlando, FL (3/7/2026).
"Non-Malignant Hematology and Novel Conditioning Strategy"

Invited Moderator / Chair / Organizer: 21 Total

89. Moderator, Stanford School of Medicine Pediatrics Research Retreat, Held online (4/21/2021).
"Faculty Talks"
90. Roundtable Chair, National Institutes of Health (NIH) and Bill & Melinda Gates Foundation (BMGF), Held online (5/11/2020).
"Expert Scientific Roundtable Webinar Meeting"
91. Panel Discussion Moderator, Center of Excellence in Regulatory Science (CERSI) - Federal Drug Administration (FDA), Held online (10/26/2021).
"Workshop on Prenatal Somatic Cell Gene Therapies"
92. Co-Host and Moderator, Chardan, Berkeley, CA (9/11-9/13/2022).
"Special People in Cellular Immunotherapy – SPICI Conference"
93. Co-Host and Moderator, Chardan, La Jolla, CA (9/10-9/12/2023).
"Special People in Cellular Immunotherapy – SPICI Conference"
94. Roundtable Chair, International Fetal Immunology and Transplantation Society (IFeTIS) Conference, Held online (10/1/2020).
"In Utero Gene Therapy Using AAV Vectors"
95. Oral Abstract Session Moderator, Transplantation and Cellular Therapy (TCT) Annual Meeting of ASTCT and CIBMTR, Salt Lake City, UT (4/23/2022).
"Session C - Immune and Gene Therapy"
96. Co-Chair and Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Los Angeles, CA (5/18/2023).
"DEI Roundtable"

97. Co-Chair and Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Stem Cell Scientific Session, Los Angeles, CA (5/20/2023).
“Emerging Opportunities in Cellular Therapies Derived from Stem Cells”
98. Co-Chair and Moderator, Fanconi Anemia Research Foundation (FARF) Scientific Symposium, Vancouver, Canada (10/1/2023).
“Gene Therapy, Gene Editing and Beyond FA”
99. Co-Organizer, National Institute of Health (NIH) Science of Conditioning Workshop, Held online (1/25/2024).
Leading to NIH Stimulating Hematology Investigation New Endeavors (SHINE) Topic NOT-DK-24-028 - “Modeling the Bone Marrow Microenvironment after Conditioning or in Non-Malignant Hematological Diseases.” Announced 8/6/2024 with subsequent solicited grant applications.
100. Moderator, Annual International Symposium on TCR $\alpha\beta$ + T-Cell/CD19+ B-Cell Depleted Haploidentical HSCT, Stanford, CA (1/31/2024).
“Focus on Bone Marrow Failure Syndromes”
101. Co-Chair and Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Prenatal Gene and Cell Therapy Scientific Session, Baltimore, MD (5/8/2024).
“Prospects for Prenatal Gene and Cell Therapy”
102. Co-Chair and Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Stem Cell Scientific Session, Baltimore, MD (5/8/2024).
“Immune Targeting and Approaches with Genetically Modified Cells and Cell Therapies”
103. Co-Chair and Moderator, Fanconi Cancer Foundation (FCF) Scientific Symposium, Charlotte, NC (10/1/2024).
“Gene Therapy, Gene Editing and Beyond in FA”
104. Panel Moderator, Fanconi Cancer Foundation (FCF) Scientific Symposium, Charlotte, NC (10/1/2024).
“Fanca-cel (RP-L102 Gene Therapy: A Potential Treatment Option for Patients with Fanconi Anemia A”
105. Co-Chair and Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Stem Cell Scientific Session, New Orleans, LA (5/15/2025).
“Next Generation Strategies for Evading Immunity in Stem Cell Therapies”
106. Co-Chair and Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Prenatal Gene and Cell Therapy Scientific Session, New Orleans, LA (5/16/2025).
“Unique Biologic Opportunities to Treat Monogenic Blood Disorders Prenatally”
107. Oral Abstract Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, New Orleans, LA (5/17/2025).
“Engineered Immune Effector Cells for Solid Tumors”
108. Co-Chair and Moderator, Fanconi Cancer Foundation (FCF) Scientific Symposium, Minneapolis, MN (9/27/2025).
“Preclinical Cell and Gene Therapy for Fanconi Anemia”
109. Moderator, Top 1000 Innovators of Poland in Silicon Valley, Stanford, CA (12/9/2025).
“Advancing Academic Collaboration Workshop - Life Science Track”

Accepted Invitations: 8 Pending

1. Speaker, Stanford Alpha Clinic, Clinical Trial Bootcamp - A Case Study on Fanconi Anemia, Stanford, CA (3/30/2026).
“Scientific Background - Nonclinical Data for Antibody-based Conditioning.”
2. Symposium Speaker, Toronto Aging Biology Annual Symposium in collaboration with the University of Toronto, Toronto, Canada (5/3/2026).
“Development of Innovative Non-Genotoxic Cell and Gene Therapies Through the Lens of Fanconi Anemia”

3. Speaker, Fanconi Anemia Europe Annual Meeting, Gdansk, Poland (5/7-8/2026).
“Non-Genotoxic Conditioning”
4. Co-Chair and Moderator, American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Stem Cell Scientific Session, Boston, MA (5/11/2026).
“In vivo Stem Cell Modulation Across Disease Systems”
5. Panelist, Stanford Genetic Therapies Rare Disease Course, Stanford, CA (6/1/2026).
6. Speaker, Immune Deficiency Foundation (IDF), National Conference, San Antonio, TX (6/25/2026).
“Less Toxic Conditioning Alternatives for Bone Marrow Transplant”
7. Session Chair, Bloom Syndrome Association (BSA), Bloom Syndrome Research & Clinical Workshop, Los Angeles, CA (7/31-8/2/2026).
“Session Translational Pathways – Gene, RNA & Small Molecule Therapies”
8. Co-Chair and Moderator, Fanconi Cancer Foundation (FCF) Scientific Symposium, Phoenix, AZ (10/1/2026).
“Preclinical Cell and Gene Therapy for Fanconi Anemia”

XV. COMMUNITY SERVICE AND INTERNATIONAL WORK

- | | |
|------|---|
| 2005 | Clinical and Public Health Intern,
Roatan Volunteer Pediatric Clinic, Roatan, Honduras. |
| 2011 | Pediatric Clinic Health Volunteer,
Little Children of the World Volunteer, Dumaguete City, Philippines. |
| 2011 | Hematology Visiting Elective Student Volunteer,
Christian Medical College, Vellore, India. |
| 2014 | Stem Cell Transplant Visiting Elective Resident Volunteer,
Hôpital Necker Enfants Malades, Paris, France. |
| 2020 | Global Consortium for Reproductive Longevity and Equality (GCRLE),
Translational Advisory Board Member,
Buck Institute for Research on Aging, Novato, CA. |

XVI. TRAINEES

Undergraduate Students:

1. Ethan Ko, Stanford University, 2019-2021, changed interests to Computer Science on AI track.
2. Gabe Seir, Stanford University, 2021-current, Bioengineering, Honors Thesis: “Development of Anti-CXCR4 Chimeric Antigen Receptor T-Cells for the Treatment of Pediatric Acute Myeloid Leukemia,” Firestone Medal for Excellence in Undergraduate Research. Accepted to several M.D./Ph.D. MSTP programs for Fall 2026.
3. Sophie Acharya, Stanford University, 2024-current, Undeclared major, Trainee in 2025 NIH R25 Hematology Inclusion Program for underrepresented and disadvantaged students.
4. Diane Joung, Stanford University, 2026-current, Undeclared major.

Post Undergraduate Trainees:

5. Emily Walck, Stanford University, 2017-2019, completed M.D. and now Pediatrics Resident at University of Minnesota. First-generation college graduate.
6. Leah Swartzrock, Iowa State University, 2020-2025, now Ph.D. Graduate Student in Yale Developmental Biology Program.

7. Kameron Peyton, W.A. Frank Honors College, 2025-current, Scholar in 2025 Stanford Medicine Postbaccalaureate Experience in Research (REACH) Program intended to provide essential training needed to advance students in their career goals and build a diverse research community.

Graduate Students:

8. Corey Cheung, University of California – San Diego M.D. Candidate, 2018-2019, HHMI Medical Research Fellow, completed Pediatrics Resident at University of California – San Francisco and now Pediatrics Urgent Care Physician at Palo Alto Medical Foundation.
9. Maite Van Hentenryck, Stanford University M.D. Candidate, 2018-2020, Medical Scholars Research, completed Pediatrics Resident at Stanford Children’s and now Pediatric Critical Care Fellow at Stanford Children’s.
10. Quenton Bubb, Stanford University M.D./Ph.D. Candidate in Stem Cell Biology and Regenerative Medicine, 2018-current, Thesis: “Development of Multivalent Cell Therapies for Treatment of Hematologic Malignancies,” American Society of Hematology (ASH) Minority Hematology Graduate Award, Paul & Daisy Soros Fellowship for New Americans, successfully defended Ph.D. thesis and now completing clinical medical school rotations. Matched in Internal Medicine Residency Physician Scientist Training Program at Cornell/MSKCC for 7/2026.
11. Andrew Burden, Stanford University Ph.D. Candidate in Stem Cell Biology and Regenerative Medicine, 2023-current, NIH NIDDK U2C-TL1 LAUNCH Fellow (co-mentor).
12. Joseph Ward, Stanford University Ph.D. Candidate in Stem Cell Biology and Regenerative Medicine, 2025-current.

Postdoctoral Scholars:

13. Dr. Pui Yan Ho (Ph.D., University of California – Davis, Davis, CA), 2018-2021, National Institutes of Health (NIH) T32 Immunology Fellow, now Senior Scientist at Gilead Sciences.
14. Dr. Supawat Thongtip (Ph.D., Rockefeller University, New York City, NY), 2019-2020, Stanford Maternal Child Health Research Institute (MCHRI) Fellow, now Assistant Vice President at RBC Capital Markets.
15. Dr. Carla Dib (Ph.D., Universite Paris-Sud, Orsay, France), 2018-2023, Stanford Maternal Child Health Research Institute (MCHRI) Fellow, now part-time Staff Scientist Czechowicz Lab.
16. Dr. Rofida Nofal (M.D., University of Zagazig School of Medicine, Zagazig, Egypt; Pediatric Hematology-Oncology Fellow, University of California – San Francisco, Benioff Children’s Hospital Oakland), 2021-2022, now Pediatrician at Santa Clara Valley Medical Center.
17. Dr. Anzhi Chen (Ph.D., Duke University, Durham, NC), 2021-2022, now Scientist at Centillion Biosciences.
18. Dr. Matthias Felber (M.D., Ernst-Moritz-Arndt-University, Greifswald, Germany), 2022 Visiting Scholar, now Attending Physician in Pediatric Hematopoietic Stem Cell Transplantation at University Children’s Hospital Zurich, Switzerland.
19. Dr. Morgane Denis (Ph.D., University of Lyon, Lyon, France), 2022-2023, now Postdoctoral Researcher at L’Institut National de la Santé et de la Recherche Médicale (INSERM).
20. Dr. Taylor Cool (Ph.D., University of California – Santa Cruz, Santa Cruz, CA), 2022-2024, National Institutes of Health (NIH) T32 Non-Malignant Hematology Fellow, NIH NIDDK LAUNCH U2C-TL1 Fellow, now Program Manager at the Institute for the Biology of Stem Cells (ISBC), University of California, Santa Cruz (UCSC).
21. Dr. Shan Huang (Ph.D., California Institute of Technology, Pasadena, CA), 2022-current, Stanford School of Medicine Dean’s Fellow and Stanford Maternal Child Health Research Institute (MCHRI) Fellow.

22. Dr. Charmaine Soco (Ph.D., City of Hope, Duarte, CA), 2022-current. Co-Chair for Justice, Equity, Diversity, & Inclusion and Community Engagement Liaison for Stanford University Postdoc Association.
23. Dr. Aaron Tan (Ph.D., Stanford University, Stanford, CA), 2025-current. Stanford Translational Research and Applied Medicine (TRAM) Grant Recipient, Stanford Pediatrics Postdoctoral Development Grant Recipient.

Rotation and Visiting Students:

24. Alex Muselman, Stanford University Ph.D. Candidate, 2018 Immunology Rotation Student.
25. William Feist, Stanford University Ph.D. Candidate, 2020 Stem Cell Biology Rotation Student.
26. Sarah Sackay, Stanford University Ph.D. Candidate, 2021 Immunology Rotation Student.
27. Julie Sanchez, Stanford University Ph.D. Candidate, 2022 Stem Cell Biology Rotation Student.
28. Lyn Portillo, Stanford University Ph.D. Candidate, 2023 Stem Cell Biology Rotation Student.
29. Saida Wiltz, St. Edward's University, 2023 College Summer Intern. Now M.D./Ph.D. MSTP Student at University of California – Los Angeles (UCLA).
30. Omar Haibe, University of Houston, 2023 College Summer Intern.
31. Christina Rouhotas, Stanford University Ph.D. Candidate, 2025 Developmental Biology Rotation Student.